• Hans-Peter Lohrmann
  • Wolfgang Schreml
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 81)


Natl Cancer Inst Cytosine Arabinoside Mouse Bone Marrow Nitrogen Mustard Hemopoietic Stem Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Abb J, Netzel B, Rodt H, Grosse-Wilde H, Weger N, Thierfelder S (1977) Hematologic and immunologic studies in dogs given nitrogen mustard (HN3). Blut 35:51–56PubMedGoogle Scholar
  2. 2.
    Abb J, Netzel B, Rodt H, Thierfelder S (1977) Effects of busulfan (bu) on hemopoiesis and immune reactivity in dogs. Biomedicine 26:403–408PubMedGoogle Scholar
  3. 3.
    Abdelnoor AM, Liang Chang H, Hong Pham P, Novotny A (1980) Lack of relationship between toxicity and bone marrow cell colony stimulating activity of endotoxin preparations. Proc Soc Exp Biol Med 163:15–18PubMedGoogle Scholar
  4. 4.
    Ahearn MJ, Lewis CW, Campbell LA, Luce JK (1967) Nuclear bleb formation in human bone marrow cells during cytosine arabinoside therapy. Nature 215:196–197PubMedGoogle Scholar
  5. 5.
    Ahmann DL, Bisel HF, Hahn RG (1974) A phase 2 evaluation of 1-(2-chloro-ethyl)-3-(4-methyl-cyclohexyl)-1-nitrosourea (NSC 95441) in patients with advanced breast cancer. Cancer Res 34:27–30PubMedGoogle Scholar
  6. 6.
    Alberts DS, van Daalen T (1976) The effect of phenobarbital on cyclophosphamide antitumor activity. Cancer Res 36:2785–2789PubMedGoogle Scholar
  7. 7.
    Alberts DS, van Daalen T (1976) The effect of allopurinol on cyclophosphamide activity. Cancer Res 36:2790–2794PubMedGoogle Scholar
  8. 8.
    Alberts DS, van Daalen T (1976) Rubidazone vs. adriamycin: an evaluation of their differential toxicity in the spleen colony assay system. Br J Cancer 34: 64–68PubMedGoogle Scholar
  9. 9.
    Alberts DS, Peng YM, Moon TE (1978) Alpha-tocopherol pretreatment increases adriamycin bone marrow toxicity. Biomedicine [Express] 29:189–191Google Scholar
  10. 10.
    Amery WK (1978) Final results of a multi-center placebo-controlled levamisole study of resectable lung cancer. Cancer Treat Rep 62:1677–1684PubMedGoogle Scholar
  11. 11.
    Ansfield F, Schroeder JM, Curreri AR (1962) Five years clinical experience with 5-fluorouracil. JAMA 181:295–299PubMedGoogle Scholar
  12. 12.
    Ansfield F, Klotz J, Nealon T, Ramirez G, Minton, J, Hill G, Wilson W, Davis H Jr, Cornell G (1977) A phase III study comparing the clinical utility of four regimens of 5-fluorouracil. Cancer 39:34–40PubMedGoogle Scholar
  13. 13.
    Apte RN, Pluznik DH (1976) Evidence for different mechanisms controlling proliferation of hemopoietic colony forming cells after stimulation with endotoxin and particulate materials. Exp Hematol 4:10–18PubMedGoogle Scholar
  14. 14.
    Asano M, Odell TT, McDonald TP, Upton AC (1963) Radiomimetic agents and X-rays in mice and AET protectiveness. Arch Pathol 75:250–263PubMedGoogle Scholar
  15. 15.
    Ash R, Chaffey JT, Hellman S (1972) The effects of nitrogen mustard on the survival of murine hematopoietic stem cells. Cancer Res 32:1695–1702PubMedGoogle Scholar
  16. 16.
    Bacchetti S, Whitmore GF (1969) Actinomycin D: Effects on mouse L cells. Biophys J 9:1427–1445PubMedGoogle Scholar
  17. 17.
    Bagley CM Jr, Bostick FW, De Vita VT Jr (1973) Clinical pharmacology of cyclophosphamide. Cancer Res 33:226–233PubMedGoogle Scholar
  18. 18.
    Baldwin RW, Pimm MV (1971) Influence of BCG-infection on growth of 3-methylcho-lanthrene-induced rat sarcomas. Eur J Clin Biol Res 16: 875–881Google Scholar
  19. 19.
    Baldwin RW, Pimm MV (1979) Tumor immunotherapy: Experimental and clinical prospects. In: Flad HD, Herfarth Ch, Betzler M (eds) Immunodiagnosis and immunotherapy of malignant tumors: Relevance to surgery. Springer, Berlin Heidelberg New York, pp 195–205Google Scholar
  20. 20.
    Barranco SC, Gerner EW, Burk KH, Humphrey RM (1973) Survival and cell kinetic effects of adriamycin on mammalian cells. Cancer Res 33:11–16PubMedGoogle Scholar
  21. 21.
    Barranco SC, Humphrey RM (1971) The effects of bleomycin on survival and cell progression in Chinese hamster cells in vitro. Cancer Res 31:1218–1223PubMedGoogle Scholar
  22. 22.
    Bateman JC, Klopp CT, Cromer JK (1951) Hematologic effects of regional nitrogen mustard therapy. Blood 6:26–38PubMedGoogle Scholar
  23. 23.
    Becker AJ, McCulloch EA, Siminovitch L, Till JE (1965) The effect of differing demands for blood cell production on DNA synthesis by hemopoietic colony-forming cells of mice. Blood 26:296–308PubMedGoogle Scholar
  24. 24.
    Belt RJ, Haas CD, Kennedy J, Taylor S (1980) Studies of hydroxyurea administered by continuous infusion. Cancer 46:455–462PubMedGoogle Scholar
  25. 25.
    Benestad HB, Breivik H (1971) Properties of hematopoietic progenitor cells. Acta Physiol Scand 83:389–398PubMedGoogle Scholar
  26. 26.
    Benestad HB, Warhuus K, Reikvam A (1977) Hydroxyurea (HU) in experimental hematology. I. Characterization of in vitro and in vivo effects on progenitor and transit cells. Exp Hematol 5:408–414PubMedGoogle Scholar
  27. 27.
    Ben-Ishay Z (1975) The lymphoid bone marrow. An experimental model. Isr J Med Sci 11:978–985PubMedGoogle Scholar
  28. 28.
    Benjamin RS, Wiernik P, Bachur NR (1974) Adriamycin chemotherapy: Efficacy, safety, and pharmacological basis of an intermittent single high-dose schedule. Cancer 33:19–27PubMedGoogle Scholar
  29. 29.
    Ben-Ishay Z, Reichert F, Sharon S (1978) Migration of lymphoid cells to the bone marrow of rat following eradication of cells in DNA synthesis and in mitosis. Experientia 34:1369–1370PubMedGoogle Scholar
  30. 30.
    Berenbaum MC, Calley M (1962) Effect of anti-tumor agents on non-dividing cells. Nature 196:656–658PubMedGoogle Scholar
  31. 31.
    Bergsagel DE, Levin WC (1960) A prelusive clinical trial of cyclophosphamide. Cancer Chemother Rep 8:120–134PubMedGoogle Scholar
  32. 32.
    Bergsagel DE, Frenkel EP, Alfrey CP Jr, Thurman WG (1964) Megaloblastic erythropoiesis induced by hydroxyurea. (NSC-32065). Cancer Chemother Rep 40:15–17Google Scholar
  33. 33.
    Bergsagel DE, Robertson GL, Hasselback R (1968) Effect of cyclophosphamide on advanced lung cancer and the hematological toxicity of large, intermittent intravenous doses. Can Med Assoc J 98:532–538PubMedGoogle Scholar
  34. 34.
    Berman J, McCabe B, Dauer MM (1969) Behavior of marrow stem cells in irradiated and nonirradiated mice after treatment with cytotoxic agents. Radiat Res 38:296–306PubMedGoogle Scholar
  35. 35.
    Bertazzoli C, Chieli T, Grandi M, Ricevuti G (1970) Adramycin: Toxicity data. Experientia 26: 389–390PubMedGoogle Scholar
  36. 36.
    Bertino JR (1977) “Rescue” techniques in cancer chemotherapy: Use of leucovorin and other rescue agents after methotrexate treatment. Semin Oncol 4:203–216PubMedGoogle Scholar
  37. 37.
    Bhuyan BK, Fraser TJ, Gray LG, Kuentzel SL, Neil LG (1973) Cell-kill kinetics of several S-phase-specific drugs. Cancer Res 33: 888–894PubMedGoogle Scholar
  38. 38.
    Bierbrauer U (1961) Die Einwirkung der Cytostatica Endoxan und Trisaethylenimino-benzochinon auf das Knochenmark und periphere Blut der Ratte. Folia Haematol (Leipz) 5:143–161Google Scholar
  39. 39.
    Bierman HR, Kelly KH, Kundson AG, Maekawa T, Timmis GM (1958) The influence of 1,4 dimethylsulfonoxy-l,4-dimethylbutane (CB 2348, dimethylmyleran) in neoplastic disease. NY Acad Sci 58:1211–1221Google Scholar
  40. 40.
    Biro V, Goldenberg DM (1971) Hematological toxicity of 1-β-D-arabinofuranosylcytosine, and its prevention by deoxycytidine, in the mouse. Chemotherapy 16:29–43PubMedGoogle Scholar
  41. 41.
    Blackett NM, Gordon MY (1978) Observations on the distribution of granulocytic progenitor cells (CFU-C) in human bone marrow. The importance of the manner in which the results of in vitro cultures are reported: Reply. Br J Haematol 40: 355–356Google Scholar
  42. 42.
    Blackett NM, Millard RE (1973) Differential effect of myleran on two normal haemopoietic progenitor cell populations. Nature 244:300–301PubMedGoogle Scholar
  43. 43.
    Blackett NM, Millard RE (1976) Different recovery patterns of mouse hemopoietic stem cells in response to cytotoxic agents. J Cell Physiol 89:473–480PubMedGoogle Scholar
  44. 44.
    Blackett NM, Millard RE, Belcher HM (1974) Thymidine suicide in vivo and in vitro of spleen colony-forming and agar colony-forming cells of mouse bone marrow. Cell Tissue Kinet 7:309–318PubMedGoogle Scholar
  45. 45.
    Blackett NM, Courtenay VD, Mayer SM (1975) Differential sensitivity of colony-forming cells of hemopoietic tissue, Lewis lung carcinoma, and B16 melanoma to three nitrosoureas. Cancer Chemother Rep 59:929–933PubMedGoogle Scholar
  46. 46.
    Blackett NM, Marsh JC, Gordon MY, Okell SF, Aguado M (1978) Simultaneous assay by six methods of the effect on haemopoietic precursor cells of adriamycin, methyl CCNU, 60Co, γ-rays, vinblastine, and cytosine arabinoside. Exp Hematol 6:2–8PubMedGoogle Scholar
  47. 47.
    Blum RH, Carter SK, Agre K (1973) A clinical review of bleomycin: A new antineoplastic agent. Cancer 31:903–914PubMedGoogle Scholar
  48. 48.
    Bock HE, Allner R, Gross R (1967) Vorteile und Nachteile der hochdosierten chemotherapeutischen Stoßbehandlung von bösartigen Geschwulstbildungen. Dtsch Med Wochenschr 92:641–646PubMedGoogle Scholar
  49. 49.
    Boeckl O, Heitz N, Karrer K, Mannheimer E (1964) Über die Möglichkeiten der Therapie bösartiger Tumoren mit hochdosierten Cytostatica. Arzneim Forsch 14:797–801Google Scholar
  50. 50.
    Boggs SS, Boggs DR (1973) Cell-cycling characteristics of exogenous spleen colony-forming units. J Lab Clin Med 82:740–753PubMedGoogle Scholar
  51. 51.
    Boggs DR, Athens JW, Haab OP, Cancilla PA, Raab SO, Cartwright GE, Wintrobe MM (1964) Leukokinetic studies. VII. Morphology of the bone marrow and blood of dogs given vinblastine sulfate. Blood 23:53–67PubMedGoogle Scholar
  52. 52.
    Boggs DR, Athens JW, Cartwright GE, Wintrobe MM (1965) Leukokinetic studies. IX. Experimental evaluation of a model of granulopoiesis. J Clin Invest 44:643–656PubMedGoogle Scholar
  53. 53.
    Boggs DR, Athens JW, Cartwright GE, Wintrobe MM (1966) The different effects of vinblastine sulfate and nitrogen mustard upon neutrophil kinetics in the dog. Proc Soc Exp Biol Med 121:1085–1090PubMedGoogle Scholar
  54. 54.
    Boggs DR, Chervenick PA, Marsh JC, Cartwright GE, Wintrobe MM (1968) Neutrophil-releasing activity in plasma of normal human subjects injected with endotoxin. Proc Soc Exp Biol Med 127: 689–693PubMedGoogle Scholar
  55. 55.
    Boggs DR, Chervenick PA, Marsh JC, Cartwright GE, Wintrobe MM (1968) Neutrophil-releasing activity in plasma of dogs injected with endotoxin. J Lab Clin Med 72:177–191PubMedGoogle Scholar
  56. 56.
    Boggs SS, Boggs DR, Neil GL, Sartiano G (1973) Cycling characteristics of endogenous spleen colony-forming cells as measured with cytosine arabinoside and methotrexate. J Lab Clin Invest 82:727–739Google Scholar
  57. 57.
    Boggs, DR, Boggs SS, Chervenick PA, Patrene KD (1980) Murine recovery from busulfan-induced hematopoietic toxicity as assessed by three assays for colony-forming cells. Am J Hematol 8:43–54PubMedGoogle Scholar
  58. 58.
    Bogliolo G, Saviane A, Massa G, Ghio R, Bianchi G, Pannacciulli I (1976) Variazioni dopo attivazione erithropoietica dell’ effetto di alcuni antiblastici. Tumori 62:445–454PubMedGoogle Scholar
  59. 59.
    Bohne F, Haas RJ, Fliedner TM, Fache I (1970) The role of slowly proliferating cells in rat bone marrow during regeneration following hydroxyurea. Br J Haematol 19:533–542PubMedGoogle Scholar
  60. 60.
    Bollag W (1957) Tierexperimentelle Untersuchungen mit dem Cytostatikum 5-Fluoro-uracil. Schweiz Med Wochenschr 87:817–820PubMedGoogle Scholar
  61. 61.
    Bonadonna G, Monfardini S, De Lena M, Fossati-Bellani F, Beretta G (1970) Phase I and preliminary phase II evaluation of adriamycin. Cancer Res 30:2572–2582PubMedGoogle Scholar
  62. 62.
    Bonadonna G, Monfardini S, De Lena M, Fossati-Bellani F, Beretta G (1972) Clinical trials with adriamycin. Result of three-years study. In: Carter SK, Di-Marco A, Ghione M et al. (eds) International symposium on adriamycin. Springer, Berlin Heidelberg New York, pp 139–152Google Scholar
  63. 62a.
    Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, De Lena M, Tancini G, Bajetta E, Musumeci R, Veronesi U (1976) Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294:405–410PubMedGoogle Scholar
  64. 63.
    Borsa J, Whitemore GF (1969) Cell killing studies on the mode of action of methotrexate on L cells in vitro. Cancer Res 29:737–744PubMedGoogle Scholar
  65. 64.
    Bosch L, Harbers E, Heidelberger Ch (1958) Studies on fluorinated pyrimidines. V. Effects on nucleic acid metabolism in vitro. Cancer Res 18: 335–343PubMedGoogle Scholar
  66. 65.
    Botnick LE, Hannon EC, Hellman S (1976) Limited proliferation of stem cells surviving alkylating agents. Nature 262:68–70PubMedGoogle Scholar
  67. 66.
    Botnick LE, Hannon EC, Hellman S (1978) Multisystem stem cell failure after apparent recovery from alkylating agents. Cancer Res 38:1942–1947PubMedGoogle Scholar
  68. 67.
    Botnick LE, Hannon EC, Hellman S (1979) Nature of the hemopoietic stem cell compartment and its proliferative potential. Blood Cells 5:195–206PubMedGoogle Scholar
  69. 68.
    Botnick LE, Hannon EC, Hellman S (1979) Late effects of cytotoxic agents on the normal tissue of mice. In: Vaeth JM (ed) Combined effects of chemotherapy and radiotherapy on normal tissue tolerance. Karger, Basel, pp 36–47Google Scholar
  70. 69.
    Bøyum A, Carsten AL, Laerum OD (1974) Haematopoiesis measured by spleen colony and diffusion chamber techniques in mice treated with one or two injections of cyclophosphamide. Br J Haematol 26:605–613PubMedGoogle Scholar
  71. 70.
    Bradley TR, Metcalf D (1966) The growth of mouse bone marrow in vitro. Aust J Exp Biol Med Sci 44:287–300PubMedGoogle Scholar
  72. 71.
    Bradley TR, Sumner MA, McInerney E (1973) Observations on enhancement of mouse marrow cell proliferation by erythrocyte extracts. In: Robinson WA (ed) Hemopoiesis in culture. DHEW Publication No. 74–205. National Institutes of Health, Bethesda, pp 77–86Google Scholar
  73. 72.
    Braunschweiger PG, Schenken LL, Schiffer LM (1980) Adriamycin-induced delayed erythropoietic injury expressed following anemia stress. Cancer Res 40:2257–2262PubMedGoogle Scholar
  74. 73.
    Breivik H (1972) Response of multipotent (CFU) and granulocyte (diffusion chamber assay) progenitor cells and differentiating cells of murine hematopoietic tissues to a perturbation of the steady state. J Cell Physiol 79:171–180PubMedGoogle Scholar
  75. 74.
    Brennan MJ, Vaitkevicius VK, Rebuck JW (1960) Megaloblastic anemia associated with inhibition of thymine synthesis (observations during 5-fluorouracil treatment). Blood 16:1535–1545Google Scholar
  76. 75.
    Briganti G, Covelli V, Silini G, Srivastava PN (1970) The distribution of erythropoietic bone marrow in the mouse. Acta Haematol 44:355–361PubMedGoogle Scholar
  77. 76.
    Briganti G, Galloni L, Levi G, Spaletta V, Mauro F (1975) Effects of bleomycin on mouse bone marrow stem cells. J Natl Cancer Inst 55:53–57PubMedGoogle Scholar
  78. 77.
    Briganti G, Levi G, Spalletta E, Galloni L, Mauro F (1980) Effect of bleomycin on mouse haemopoietic colony-forming cells in culture (CFU-C). Cell Tissue Kinet 13:145–151PubMedGoogle Scholar
  79. 78.
    Brown CH, Carbone PP (1971) Effects of chemotherapeutic agents on normal mouse bone marrow grown in vitro. Cancer Res 31:185–190PubMedGoogle Scholar
  80. 79.
    Broxmeyer HE, Galbraith PR, Baker FL (1976) Relationship of colony-stimulating activity to apparent kill of human colony-forming cells by irradiation and hydroxyurea. Blood 47:403–411PubMedGoogle Scholar
  81. 80.
    Bruce WR, Meeker BE (1967) Comparison of the sensitivity of haematopoietic colony-forming cells in different proliferative states to 5-Fluorouracil. J Natl Cancer Inst 38:401–405PubMedGoogle Scholar
  82. 81.
    Bruce WR, Meeker BE, Valeriote FA (1966) Comparison of the sensitivity of normal hematopoietic and transplanted lymphoma colony-forming cells to chemotherapeutic agents administered in vivo. J Natl Cancer Inst 37:233–245PubMedGoogle Scholar
  83. 82.
    Bruce WR, Meeker BE, Powers WE, Valeriote FA (1969) Comparison of the dose- and time-survival curves for normal hematopoietic and lymphoma colony-forming cells exposed to vinblastine, vincristine, arabinosylcytosine, and amethopterin. J Natl Cancer Inst 42:1015–1023PubMedGoogle Scholar
  84. 83.
    Bruce DL, Lin H-S, Bruce WR (1970) Reduction of colony-forming cell sensitivity to arabinosylcytosine by halothane anesthesia. Cancer Res 30:1803–1805PubMedGoogle Scholar
  85. 84.
    Buckner CD, Briggs R, Clift RA, Fefer A, Funk DD, Glucksberg H, Neiman PE, Storb R, Thomas ED (1974) Intermittent high-dose cyclophosphamide (NSC-26271) treatment of stage III ovarian carcinoma. Cancer Chemother Rep 58:697–703PubMedGoogle Scholar
  86. 85.
    Buckner CD, Clift RA, Fefer A, Funk DD, Glucksberg H, Neiman PE, Paulsen A, Storb R, Thomas ED (1974) High-dose cyclophosphamide (NSC-26271) for the treatment of metastatic testicular neoplasms. Cancer Chemother Rep 58:709–714PubMedGoogle Scholar
  87. 86.
    Buckner CD, Dillingham LA, Giddens WE, Thomas ED (1975) Toxicologic and marrow transplantation studies in Rhesus monkeys given dimethyl myleran. Exp Hematol 3:275–288PubMedGoogle Scholar
  88. 87.
    Buckner CD, Rudolph RH, Fefer A, Clift RA, Epstein RB, Funk DD, Neiman PE, Slichter SJ, Storb R, Thomas ED (1972) High-dose cyclophosphamide therapy for malignant disease. Toxicity, tumor response, and the effects of stored autologous marrow. Cancer 29:357–365Google Scholar
  89. 88.
    Buhles W-C, Shifrine M (1978) Increased bone marrow production of granulocytes and mononuclear phagocytes induced by mycobacterial adjuvants: Improved recovery of leukopoiesis in mice after cyclophosphamide treatment. Infect Immun 20:58–65PubMedGoogle Scholar
  90. 89.
    Buick RN, Messner HA, Till JE, McCulloch EA (1979) Cytotoxicity of adriamycin and daunorubicin for normal and leucemic progenitor cells of man. J Natl Cancer Inst 62:249–255PubMedGoogle Scholar
  91. 90.
    Burgess AW, Wilson MA, Metcalf D (1977) Stimulation by human placental conditioned medium of hemopoietic colony formation by human bone marrow cells. Blood 49:573–583PubMedGoogle Scholar
  92. 91.
    Burke PJ, Serpick AA, Carbone PP, Tarr N (1968) A clinical evaluation of dose and schedule of administration of cytosine arabinoside (NSC 63878). Cancer Res 28:274–279PubMedGoogle Scholar
  93. 92.
    Burke PJ, Owens AH, Colsky J, Shnider BI, Edmonson JH, Schilling A, Brodovsky HS, Wallace HJ, Hall TC (1970) A clinical evaluation of a prolonged schedule of cytosine arabinoside (NSC 63878). Cancer Res 30:1512–1515PubMedGoogle Scholar
  94. 93.
    Burke PJ, McCarthy WH, Milton GW (1971) Imidazole carboxamide therapy in advanced malignant melanoma. Cancer 27:744–750PubMedGoogle Scholar
  95. 94.
    Buroker TH, Padilla F, Groppe C, Guy G, Quagliana J, McCracken J, Vaitkevicius VK, Hoogstraaten B, Heilbrun L (1979) Phase II evaluation of ftorafur in previously untreated colorectal cancer. Cancer 44:48–51PubMedGoogle Scholar
  96. 95.
    Byron JW (1975) Cholinergic mechanisms and the hemopoietic stem cell. In: Nakao K, Fisher JW, Takaku F (eds) (1975) Erythropoiesis. Proc 4th Int. Conf. Erythropoiesis, Tokyo, 1975. University of Tokyo Press, Tokyo, pp 141–149Google Scholar
  97. 96.
    Byron JW (1972) Comparison of the action of 3H-thymidine and hydroxyurea on testosterone-treated hemopoietic stem cells. Blood 40:198–203PubMedGoogle Scholar
  98. 97.
    Cameron GR, Courtice FC, Jones RP (1947) The effects of β,β′-dichlorodiethyl methylamine hydrochloride on the blood-forming tissues. J Pathol Biol 59:425–435Google Scholar
  99. 98.
    Camplejohn RS, Schultze B, Maurer W (1977) In vivo cell synchrony in the L1210 mouse leukaemia studied with 5-fluorouracil or 5-fluorouracil followed by cold thymidine infusion. Br J Cancer 35:546–556PubMedGoogle Scholar
  100. 99.
    Carbone PP, Bono V, Frei E, Brindley CO (1963) Clinical studies with vincristine. Blood 21:640–644PubMedGoogle Scholar
  101. 100.
    Carter SK, Friedman MA (1972) 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC, DIC, NSC-45388). A new antitumor agent with activity against malignant melanoma. Eur J Cancer 8:85–92PubMedGoogle Scholar
  102. 101.
    Carter SK, DiMarco A, Ghione M, Krakoff JH, Mathé G (eds) (1972) International symposium on adriamycin. Springer, Berlin Heidelberg New YorkGoogle Scholar
  103. 102.
    Carter SK, Schabel FM, Broder LE, Johnston TP (1972) 1,3-bis(2-chloroethyl)-1-nitro-sourea (BCNU) and other nitrosoureas in cancer treatment: A review. Adv Cancer Res 16:273–332PubMedGoogle Scholar
  104. 103.
    Cartwright GE, Athens JW, Boggs DR, Wintrobe MM (1965) The kinetics of granulopoiesis in normal man. Ser Hematol 1:1–12Google Scholar
  105. 104.
    Casanyi E, Elson LA (1967) Action of “mustard” and “myleran” type alkylating agents on the cellular proliferation and DNA metabolism of the haemopoietic organs of the rat. Br Empire Cancer Campaign Res 45:32–33Google Scholar
  106. 105.
    Cavins JA, Scheer SC, Thomas ED, Ferrebee JW (1964) The recovery of lethally irradiated dogs given infusions of autologous leukocytes preserved at -80° C. Blood 23:38–43PubMedGoogle Scholar
  107. 106.
    Chaffey JF, Hellman S (1971) Differing responses to radiation of murine bone marrow stem cells in relation to the cell cycle. Cancer Res 31:1613–1615PubMedGoogle Scholar
  108. 107.
    Chen MG, Schooley JC (1970) Recovery of proliferative capacity of agar colony-forming cells and spleen colony-forming cells following ionizing radiation or vinblastine. J Cell Physiol 75:89–96PubMedGoogle Scholar
  109. 108.
    Chervenick PA (1972) Effect of endotoxin and postendotoxin plasma on in vitro granulopoiesis. J Lab Clin Med 79:1014–1020PubMedGoogle Scholar
  110. 109.
    Chervenick PA, Boggs DR (1971) Patterns of proliferation and differentiation of hematopoietic stem cells after compartment depletion. Blood 37:568–580PubMedGoogle Scholar
  111. 110.
    Chervenick PA, LoBuglio AF (1972) Human blood monocytes: Stimulators of granulocyte and mononuclear colony formation in vitro. Science 178:164–166PubMedGoogle Scholar
  112. 111.
    Chervenick PA, Boggs DR, Marsh JC, Cartwright GE, Wintrobe MM (1968) Quantitative studies of blood and bone marrow neutrophils in normal mice. Am J Physiol 215:353–360PubMedGoogle Scholar
  113. 112.
    Chlebowski RT, Hestorff R, Sardoff L, Weiner J, Bateman JR (1978) Cyclophosphamide (NSC 26271) versus the combination of adriamycin (NSC 123127), 5-fluorouracil (NSC 19893), and cyclophosphamide in the treatment of metastatic prostatic cancer: A randomized trial. Cancer 42:2546–2552PubMedGoogle Scholar
  114. 112a.
    Clement JJ, Gorman MS, Wodinsky I, Catane R, Johnson RK (1980) Enhancement of antitumor activity of alkylating agents by the radiation sensitizer misonidazole. Cancer Res 40:4165–4172PubMedGoogle Scholar
  115. 113.
    Clifford P, Clift RA, Khan AG, Timmis GM (1964) Dimethyl myleran therapy combined with abdominal aortic occlusion. Br J Cancer 18:435–448Google Scholar
  116. 114.
    Cline MJ, Golde D (1977) Mobilization of hematopoietic stem cells (CFU-C) into the peripheral blood of man by endotoxin. Exp Hematol 5:186–190PubMedGoogle Scholar
  117. 115.
    Cline MJ, Rothman B, Golde D (1974) Effect of endotoxin on the production of colony-stimulating factor by human monocytes and macrophages. J Cell Physiol 84:193–196PubMedGoogle Scholar
  118. 116.
    Coggins PR, Ravdin RG, Eisman SH (1960) Clinical evaluation of a new akylating agent: Cytoxan (cyclophosphamide). Cancer 13:1254–1260PubMedGoogle Scholar
  119. 117.
    Cohen AM (1975) The disposition of ftorafur in rats after intravenous administration. Drug Metab Dispos 3:303–308PubMedGoogle Scholar
  120. 118.
    Cohen SS, Flaks JG, Barner HD, Loeb MR, Lichtenstein J (1958) The mode of action of 5-fluorouracil and its derivatives. Proc Natl Acad Sci USA 44:1004–1012PubMedGoogle Scholar
  121. 119.
    Cohen JL, Jao JY, Jusko WJ (1971) Pharmacokinetics of cyclophosphamide in man. Br J Pharmacol 43:677–680PubMedGoogle Scholar
  122. 120.
    Coiffier B, Sicard B, Bryon PA, Germain D (1980) Observations on human bone marrow granulocytic progenitor cell culture: A comparison of two ways to express results. Br J Haematol 44:335–337PubMedGoogle Scholar
  123. 121.
    Colvin M, Santos G (1970) High-dose cyclophosphamide administration. Proc Am Assoc Cancer Res 11:17Google Scholar
  124. 122.
    Condit PT (1960) Studies on the folic acid vitamins. II. The acute toxicity of amethopterin in man. Cancer 13: 222–228PubMedGoogle Scholar
  125. 123.
    Connors TA, Roberts JJ (eds) (1974) Platinum coordination complexes in cancer chemotherapy. Springer, Berlin Heidelberg New York. Recent Results in Cancer Research, vol 48Google Scholar
  126. 124.
    Constable TB, Blackett NM (1972) Comparison of effect of four cytotoxic agents on granulocytic and erythroid repopulating ability of rat bone marrow. J Natl Cancer Inst 48:941–948PubMedGoogle Scholar
  127. 125.
    Constable TB, Blackett NM (1973) Effect of cytotoxic atents on the maturing granulocytic and erythroid cells of rats. J Natl Cancer Inst 50: 515–521PubMedGoogle Scholar
  128. 126.
    Constable TB, Blackett NM (1974) The relationship between granulocytic and erythroid repopulating ability. Exp Hematol 2:131–137PubMedGoogle Scholar
  129. 127.
    Cook PA, Page PL, Greenberg HM, Hartwell BL, Robinson SH (1977) Recovery of hemopoietic stem cells in mouse bone marrow after depletion by chemotherapy (Abstr). Blood [Suppl 1] 50:143Google Scholar
  130. 128.
    Corder MP, Jochimsen PR, Dick FR (1979) Abnormal peripheral neutrophil and white blood cell stimulation in patients treated for regional carcinoma of the breast with adjuvant therapy (Abstr). Clin Res 37:383Google Scholar
  131. 128.
    Corder MP, Jochimsen PR, Dick FR (1979) Abnormal peripheral neutrophil and white blood cell stimulation in patients treated for regional carcinoma of the breast with adjuvant therapy (Abstr). Clin Res 37:383Google Scholar
  132. 129.
    Costa G, Hreshchyshyn MM, Holland JF (1962) Initial clinical studies with vincristine. Cancer Chemother Rep 24:39–44PubMedGoogle Scholar
  133. 130.
    Costanza ME, Nathanson L, Lenhard R, Wolter J, Colsky J, Oberfield RA, Schilling A (1972) Therapy of malignant melanoma with an imidazole carboxamide and bis-chloro-ethyl nitrosurea. Cancer 30:1457–1461PubMedGoogle Scholar
  134. 131.
    Cowan DH, Bergsagel DE (1971) Intermittent treatment of metastatic malignant melanoma with high-dose 5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388). Cancer Chemother Rep Part 1 55:175–181Google Scholar
  135. 132.
    Craddock CG Jr, Perry S, Ventzke LE, Lawrence JS (1960) Evaluation of marrow granulocyte reserves in normal and disease states. Blood 15:840–855PubMedGoogle Scholar
  136. 133.
    Croizat H, Frindel E, Tubiana M (1970) Proliferative activity of the stem cells in the bone marrow of mice after single and multiple irradiations (total- and partial-body exposure). Int J Radiat Biol 18:347–358Google Scholar
  137. 134.
    Cronkite EP, Vincent PC (1969) Granulocytopoiesis. Ser Hematol II/4:3–43Google Scholar
  138. 135.
    Cronkite EP, Bond VP, Fliedner TM, Killmann S-A (1960) The use of tritiated thymidine in the study of haemopoietic cell proliferation. In: Wolstenholme GEW, O’Connor M (eds) Ciba foundation symposium on haemopoiesis. Churchill, London, pp 70–92Google Scholar
  139. 136.
    Csany E, Elson LA (1967) Action of “mustard-” and “myleran-” type alkylating agents on the cellular proliferation and DNA metabolism of the haemopoietic organs of the rat. Br Empire Cancer Campaign Res 45:32–33Google Scholar
  140. 137.
    Cutts JH (1968) Protective action of diethylstilbestrol on the toxicity of vinblastine in rats. J Natl Cancer Inst 41:919–922PubMedGoogle Scholar
  141. 138.
    Cvitkovic E, Spaulding J, Betune V, Martin J, Whitmore WF (1977) Improvement of cis-dichlordiamine platinum (NSC-119875): Therapeutic index in an animal model. Cancer 39:1357–1361PubMedGoogle Scholar
  142. 139.
    Dahlgren S, Holm G, Svanborg N, Ragnar W (1972) Clinical and morphological side-effects of busulfan (myleran) treatment. Acta Med Scand 192:129–135PubMedGoogle Scholar
  143. 140.
    Dale DC, Fauci AS, Wolff SM (1973) The effect of cyclophosphamide on leukocyte kinetics and susceptibility to infection in patients with Wegener’s granulomatosis. Arthritis Rheum 16:657–664PubMedGoogle Scholar
  144. 141.
    Dale DC, Fauci AS, Guerry D, Wolff SM (1975) Comparison of agents producing a neutrophilic leukocytosis in man. Hydrocortisone, prednisone, endotoxin, and etiochol-anolone. J Clin Invest 56:808–813PubMedGoogle Scholar
  145. 142.
    Dameshek W, Weisbuse L, Stein T: Nitrogen mustard therapy in Hodgkin’s disease. Blood 4:338–379Google Scholar
  146. 143.
    Dancey JT, Deubelbeiss KA, Harker LA, Finch CA (1976) Neutrophil kinetics in man. J Clin Invest 58:705–715PubMedGoogle Scholar
  147. 144.
    Deinard AS, Fortuny IE, Theologides A, Anderson GL, Boen J, Kennedy BJ (1974) Studies on the neutropenia of cancer chemotherapy. Cancer 33:1210–1218PubMedGoogle Scholar
  148. 145.
    Delmonte L (1978) Effect of myleran on murine hemopoiesis. I. Granulocytic cell line specificity of action on progenitor cells. Cell Tissue Kinet 11:347–358PubMedGoogle Scholar
  149. 146.
    Delmonte L (1978) Effect of myleran on murine hemopoiesis. II. Direct and host-mediated action on proliferative capacity and differentiation bias of spleen colony forming units (CFU-S). Cell Tissue Kinet 11:359–367PubMedGoogle Scholar
  150. 147.
    Delmonte L, Williams N, Moore MAS (1978) Effect of myleran on murine hemopoiesis. III. Changes in the density distribution of spleen colony forming (CFU-S) and agar gel colony forming cells (CFU-C). Cell Tissue Kinet 11: 369–375PubMedGoogle Scholar
  151. 148.
    Denine EP, Harrison SD, Peckham JC (1977) Qualitative and quantitative toxicity of sublethal doses of methyl-CCNU in BDF1 mice. Cancer Treat Rep 61:409–417PubMedGoogle Scholar
  152. 149.
    De Palo GM, De Lena M, Di Re F, Luciani L, Valagussa P, Bonadonna G (1975) Melphalan versus adriamycin in the treatment of advanced carcinoma of the ovary. Surg Gynecol Obstet 141:899–902PubMedGoogle Scholar
  153. 150.
    Deprez-deCampeneere D, Baurain R, Trouet A (1979) Pharmacokinetic, toxicologic, and chemotherapeutic properties of detrorubicin in mice: A comparative study with daunorubicin and adriamycin. Cancer Treat Rep 63:861–867Google Scholar
  154. 151.
    Deubelbeiss KA, Dancy JT, Harker LA, Cheney B, Finch CA (1975) Marrow erythroid and neutrophil cellularity in the dog. J Clin Invest 55: 825–832Google Scholar
  155. 152.
    De Vita VT, Gold GL, Owens AH, Miller JM (1964) Preliminary studies with l,3-bis-(2-chloroethyl)-l-nitrosourea (BCNU) (Abstr). Proc Amer Ass Cancer Res 5:15Google Scholar
  156. 153.
    De Vita VT, Carbone PP, Owens AH, Gold GL, Krant MJ, Edmonson J (1965) Clinical trials with 1,3-bis(2-chloroethyl)-1-nitrosourea (NSC-409962). Cancer Res 25:1876–1881PubMedGoogle Scholar
  157. 154.
    De Wys WJ, Mansky JM (1973) Delayed hematological recovery after cyclophosphamide treatment in the presence of an advanced tumor. Cancer Res 33:2662–2667Google Scholar
  158. 155.
    De Wys WD, Goldin A, Mantel N (1970) Hematopietic recovery after large doses of cyclophosphamide: Correlation of proliferative state with sensitivity. Cancer Res 30:1692–1697Google Scholar
  159. 156.
    Di Marco A (1975) Adriamycin (NSC-12327): Model and mechanisms of action. Cancer Chemother Rep 59:91–106Google Scholar
  160. 157.
    Di Marco A, Gaetani M, Dorigotti L, Soldati M, Bellini O (1964) Daunomycin: A new antibiotic with antitumor activity. Cancer Chemother Rep 38:31–38Google Scholar
  161. 158.
    Donaldson RC (1972) Methotrexate plus bacillus Calmette-Guérin (BCG) and isoniazid in the treatment of cancer of the head and neck. Am J Surg 124: 527–534PubMedGoogle Scholar
  162. 159.
    Donohue DM, Gabrio BW, Finch CA (1958) Quantitative measurement of hematopoietic cells of the marrow. J Clin Invest 37:1564–1575PubMedGoogle Scholar
  163. 160.
    Donohue DM, Reiff RH, Hanson ML, Betson Y, Finch CA (1958) Quantitative measurement of the erythrocytic and granulocytic cells of the marrow and blood. J Clin Invest 37:1571–1576PubMedGoogle Scholar
  164. 161.
    Douglas IDC, Price LA (1973) Bone marrow toxicity of methotrexate: A reassessment. Br J Haematol 24:625–631PubMedGoogle Scholar
  165. 162.
    Dresch C, Faille A, Poirier O, Balitrand N, Najean Y (1979) Hydroxurea suicide study of the kinetic heterogeneity of colony-forming cells in human bone marrow. Exp Haematol 7:337–344Google Scholar
  166. 163.
    Drew RM, Painter RB (1959) Action of tritiated thymidine on the clonal growth of mammalian cells. Radiat Res 11:535–544PubMedGoogle Scholar
  167. 164.
    Droz JP, Mordaret N, Charbord P, Maraninchi D, Hayat M, Parmentier C (1977) Chemotherapy of differentiated thyroid carcinomas. Clinical results and effects on the granulocytic stem cell (CFU-C) compartment. Ann Radiol (Paris) 20:814–818Google Scholar
  168. 165.
    Duménil D, Sainteny F, Frindel E (1979) Some effects of chemotherapeutic drugs on bone marrow stem cells. Cancer Chemother Pharmacol 2:197–201PubMedGoogle Scholar
  169. 166.
    Dunn CDR (1972) The effect of certain nitrogen mustard derivatives on bone marrow colony-forming units and erythroid repopulating ability. I. Rats. Eur J Cancer 8:509–516Google Scholar
  170. 167.
    Dunn CDR (1972) The effect of certain nitrogen mustard derivatives on bone marrow colony-forming units and erythroid repopulating ability. II. Mice. Eur J Cancer 8:517–522Google Scholar
  171. 168.
    Dunn CDR (1972) Cell proliferation and drug resistance in the response of colony-forming units of rat bone marrow to repeated doses of cytotoxic agents. J Natl Cancer Inst 48:639–649PubMedGoogle Scholar
  172. 169.
    Dunn CDR (1973) The proliferative capacity of haemopoietic colony forming units in the rat. Cell Tissue Kinet 6:55–67PubMedGoogle Scholar
  173. 170.
    Dunn CDR (1974) Effect, with time, of melphalan on hematopoietic stem cells proliferating at different rates. J Natl Cancer Inst 52:173–180PubMedGoogle Scholar
  174. 171.
    Dunn CDR (1974) The chemical and biological properties of busulphan (‘Myleran’). Exp Hematol 2:101–117PubMedGoogle Scholar
  175. 172.
    Dunn CDR, Constable TB (1973) A comparison of the three in vivo assays for haemopoietic stem cells. Acta Haematol 50:9–18PubMedGoogle Scholar
  176. 173.
    Dunn CDR, Elson LA (1970) An apparent discrepancy between the number of colony forming units transplanted and survival of busulphan lethally treated rats. J Cell Physiol 76:215–224PubMedGoogle Scholar
  177. 174.
    Dunn CDR, Elson LA (1970) The comparative effect of busulphan (‘myleran’) and aminochlorambucil on haemopoietic colony forming units in the rat. Cell Tissue Kinet 3:131–141PubMedGoogle Scholar
  178. 175.
    Eaves AC, Bruce WR (1972) Endotoxin-induced sensitivity of hematopoietic stem cells to chemotherapeutic agents. Ser Haematol 5/2:64–72PubMedGoogle Scholar
  179. 176.
    Eaves AC, Bruce WR (1974) Altered sensitivity of hematopoietic stem cells to 5-fluorouracil (NSC-19893) following endotoxin (NSC-189681), cyclophosphamide (NSC-26271), or irradiation. Cancer Chemother Rep 58:813–820PubMedGoogle Scholar
  180. 177.
    Edelstein M, Vietti T, Valeriote F (1974) Schedule-dependent synergism for the combination of 1-β-D-arabinofuranosylcytosine and daunorubicin. Cancer Res 34:293–297PubMedGoogle Scholar
  181. 178.
    Edelstein M, Vietti T, Valeriote F (1975) The enhanced cytotoxicity of combinations of 1-β-D-arabinofuranosylcytosine and methotrexate. Cancer Res 35:1555–1558PubMedGoogle Scholar
  182. 179.
    Eliopoulos GD, André S, Anagnou NP, Fessas P (1979) Prolonged effect of Corynebacterium parvum stimulation on granulopoiesis. Scand J Haematol 23:353–359PubMedGoogle Scholar
  183. 180.
    Eliopoulos G, André S, Meletis J, Tselentis J, Halpern B (1980) Effect of Corynebacterium parvum stimulation on granulopoiesis. Eur J Cancer 16:1093–1098PubMedGoogle Scholar
  184. 181.
    Ellis RE (1961) Distribution of active bone marrow in the adult. Phys Med Biol 5:255–258PubMedGoogle Scholar
  185. 182.
    Ellison RR, Carey RW, Holland JF (1967) Continuous infusions of arabinosyl cytosine in patients with neoplastic disease. Clin Pharmacol Ther 8:800–809PubMedGoogle Scholar
  186. 183.
    Elson LA (1955) A comparison of the effects of radiation and radiomimetic chemicals on the blood. Br J Haematol 1:104–116PubMedGoogle Scholar
  187. 184.
    Elson LA (1958) Hematological effects of the alkylating agents. Ann NY Acad Sci 68:826–833PubMedGoogle Scholar
  188. 185.
    Elson LA, Galton DAG, Morwenna T (1958) The action of chlorambucil (CB. 1348) and busulphan (myleran) on the haemopoietic organs of the rat. Br J Haematol 4:355–371PubMedGoogle Scholar
  189. 186.
    Epstein RB, Storb R, Clift RA, Thomas ED (1969) Autologous bone marrow grafts in dogs treated with lethal doses of cyclophosphamide. Cancer Res 29:1072–1075PubMedGoogle Scholar
  190. 187.
    Evans R, Madison LD, Eidlen DM (1980) Cyclophosphamide-induced changes in the cellular composition of a methylcholanthrene-induced tumor and their relation to bone marrow and blood leukocyte levels. Cancer Res 40:395–402PubMedGoogle Scholar
  191. 188.
    Fabricius E, Rajewsky MF (1971) Determination of hydroxyurea in mammalian tissues and blood. Rev Eur Etud Clin 16:679–683Google Scholar
  192. 189.
    Fairman E, Corner GW (1934) The bone marrow volume of the albino rat. Anat Rec 60:1–4Google Scholar
  193. 190.
    Fairman E, Whipple GH (1933) Bone marrow volume in adult dogs. Am J Physiol 104:352–357Google Scholar
  194. 191.
    Falkson G, Moertel CG, Lavin P, Pretorius FJ, Carbone PP (1978) Chemotherapy studies in primary liver cancer: A prospective randomized clinical trial. Cancer 42:2149–2156PubMedGoogle Scholar
  195. 192.
    Fehér J, Gidali J (1980) Protection of cycling CFU-S against hydroxyurea by low doses of actinomycin D. Cell Tissue Kinet 13:415–424PubMedGoogle Scholar
  196. 193.
    Fehir KM, Rossof AH (1977) Lithium carbonate (LC) stimulation of marrow colony-forming units (CFU-c) and peripheral granulocytes (PMN) in a canine model (Abstr). Blood [Suppl 1] 50:145Google Scholar
  197. 194.
    Ferguson FC Jr, Thiersch JB, Philips FS (1950) The action of 4-amino-N10-methyl-pte-roylglutamic acid in mice, rats, and dogs. J Pharmacol Exp Ther 98:293–299PubMedGoogle Scholar
  198. 195.
    Ferguson RJ, Webber RH, Hayes ER (1975) Suppression and regeneration of rat bone marrow under the influence of methotrexate. Acta Anat (Basel) 92:481–512Google Scholar
  199. 196.
    Fewer D, Wilson CB, Boldrey EB, Enot JK (1972) Phase II study of 1-(2-chloro-ethyl)-3-cyclohexyl-1-nitrosourea (CCNU; NSC-79037) in the treatment of brain tumors. Cancer Chemother Rep 56:421–427PubMedGoogle Scholar
  200. 197.
    Finch CA, Harker LA, Cook JD (1977) Kinetics of the formed elements of human blood. Blood 50:699–707PubMedGoogle Scholar
  201. 198.
    Fink ME, Calabresi P (1962) The granulocyte response to an endotoxin (Pyrexal) as a measure of functional marrow reserve in cancer chemotherapy. Ann Intern Med 57:732–742Google Scholar
  202. 199.
    Finkelstein JZ, Hittle RE, Hammond GD (1969) Evaluation of a high-dose cyclophosphamide regimen in childhood tumors. Cancer 23:1239–1242Google Scholar
  203. 200.
    Finley WH, Carlson WW, Frommeyer WB, Woods JW (1964) The bone marrow depressant and antitumor properties in animals of some new alkylating agents. Cancer 17:1271–1277PubMedGoogle Scholar
  204. 201.
    Fisher B, Gebhardt M (1978) Comparative effects of Corynebacterium parvum, Brucella abortus extract, Bacillus Calmette-Guérin, Glucan, levamisole, and Tilorone with or without cyclophosphamide on tumor growth, macrophage production, and macrophage cytotoxicity in a murine mammary tumor model. Cancer Treat Rep 62:1919–1930PubMedGoogle Scholar
  205. 202.
    Fitchen JH, Cline MJ (1980) The effect of granulopoietic stress in mice with “latent” bone marrow failure. Exp Hematol 8:788–794PubMedGoogle Scholar
  206. 203.
    Fliedner TM (1974) Kinetic und Regulationsmechanismen des Granulozytenumsatzes. Schweiz Med Wochenschr 104:98–107PubMedGoogle Scholar
  207. 203a.
    Floersheim GL, Elson LA (1961) Wiederherstellung der Hämatopoiese nach letaler Dosis von Dimethyl-Myleran durch isologe Knochenmarkstransplantation bei Mäusen. Versuche zur Beeinflussung der Intoleranz gegenüber homologem Knochenmark durch 6-Mercaptopurin, Aminochlorambucil und Cortison. Acta Haematol 26:233–245PubMedGoogle Scholar
  208. 204.
    Foster RS (1976) The immunostimulant Corynebacterium parvum and hematopoietic toxicity of chemotherapy. Surg Forum 27:140–142PubMedGoogle Scholar
  209. 205.
    Foster RS (1978) Effects of Corynebacterium parvum on granulocyte/macrophage production and toxicity of chemotherapy. Dev Biol Stand 38:245–251Google Scholar
  210. 206.
    Foster RS (1978) Effect of Corynebacterium parvum on the proliferative rate of granulocyte-macrophage progenitor cells and the toxicity of chemotherapy. Cancer Res 38:2666–2672PubMedGoogle Scholar
  211. 207.
    Foster RS (1978) Altered toxicity of 5-fluorouracil following treatment with Corynebacterium parvum. Cancer Res 38: 850–858PubMedGoogle Scholar
  212. 208.
    Foster RS, MacPherson BR, Browdie DA (1977) Effect of Corynebacterium parvum on colony-stimulating factor and granulocyte-macrophage colony formation. Cancer Res 37:1349–1355PubMedGoogle Scholar
  213. 209.
    Fox PA, Panasci LC, Schein PS (1977) Biological and biochemical properties of 1-(2-chloroethyl)-3(β-D-glucopyranosyl)-1-nitrosourea (NSC 254157), a nitrosourea with reduced bone marrow toxicity. Cancer Res 37:783–787PubMedGoogle Scholar
  214. 210.
    Fox RM, Woods RL, Tattersall MHN, Brodie GM (1979) Allopurinol modulation of high-dose fluorouracil toxicity. Lancet I: 677Google Scholar
  215. 211.
    Foyer LV, Chapman ChG, Willett FM, Adams WS (1960) Cyclophosphamide: A preliminary study of a new alkylating agent. Cancer Chemother Rep 6:39–40Google Scholar
  216. 212.
    Fred SS, Smith WW (1968) Induced changes in transplantability of hemopoietic colony-forming cells. Proc Soc Exp Biol Med 128:364–366PubMedGoogle Scholar
  217. 213.
    Frederickson T, Tambourin P, Wendling F, Jasmin C, Smajda F (1975) Target cell of the polycythemia-inducing Friend virus: Studies with myleran. J Natl Cancer Inst 55:443–445Google Scholar
  218. 214.
    Freeman CB, Harris R, Geary CG, Leyland MJ, Mclver JE, Delamore IW (1973) Active immunotherapy used alone for maintenance of patients with acute myeloid leukaemia. Br Med J 4:571–573PubMedGoogle Scholar
  219. 215.
    Frei E, Franzino A, Shnider B, Costa G, Colsky J, Brindley CO, Hosley H, Holland JF, Gold GL, Jonsson U (1961) Clinical studies with vinblastine. Cancer Chemother Rep 12:125–129PubMedGoogle Scholar
  220. 216.
    Frei E, Whang J, Scoggins RB, van Scott EJ, Rall DP, Ben M (1964) The stathmokinetic effect of vincristine. Cancer Res 24:1918–1925PubMedGoogle Scholar
  221. 217.
    Frei E, Bickers JN, Hewlett JS, Lane M, Leary WV, Talley RW (1969) Dose schedule and antitumor studies of arabinosyl cytosine (NSC 63878). Cancer Res 29:1325–1332PubMedGoogle Scholar
  222. 218.
    Fried W, Barone J (1980) Residual marrow damage following therapy with cyclophosphamide. Exp Hematol 8:610–614PubMedGoogle Scholar
  223. 219.
    Fried W, Johnson C (1968) The effect of cyclophosphamide on hematopoietic stem cells. Radiat Res 36:521–527PubMedGoogle Scholar
  224. 220.
    Fried W, Gregory S, Knospe WH, Trobaugh FE Jr (1970) Stimulus to proliferation of hemopoietic stem cells following injection of cyclophosphamide. Exp Hematol 20:11–15Google Scholar
  225. 221.
    Fried W, Kedo A, Barone J (1977) Effects of cyclophosphamide and of busulfan on spleen colony-forming units and on hematopoietic stroma. Cancer Res 37:1205–1209PubMedGoogle Scholar
  226. 222.
    Frindel E, Dumenil D, Sainteny F (1980) Role of pluripoietins in murine bone marrow stem cell differentiation. Leuk Res 4:287–299PubMedGoogle Scholar
  227. 223.
    Fujimoto S, Inouyi T, Tsukagoshi S (1976) Effect of drug combination on antitumor activity and myelotoxicity. Gann 67:207–211PubMedGoogle Scholar
  228. 224.
    Galton DAG, Morwenna T, Wiltschaw E (1958) Busulfan (1,4-dimethanesolfonyloxy-butane, myleran): Summary of clinical results. Ann NY Acad Sci 68:967–973PubMedGoogle Scholar
  229. 225.
    Gerner RE, Moore GE (1973) Study of 5-(3,3-Dimethyl-1-triazeno)imidazole-4-carbox-amide (NSC-45388) in patients with disseminated melanoma. Cancer Chemother Rep Part 1 57:83–84Google Scholar
  230. 226.
    Gerson SL, Page PL, Hartwell BL, Robinson SH (1977) Altered proliferative capacity of hemopoietic cells after cytotoxic perturbation (Abstr). Blood [Suppl 1] 50:147Google Scholar
  231. 227.
    Gidáli J, Lajtha LG (1972) Regulation of haemopoietic stem cell turnover in partially irradiated mice. Cell Tissue Kinet 5:147–157PubMedGoogle Scholar
  232. 228.
    Gidáli J, Fehér I, Várterész V (1969) The effect of endotoxin on the growth and differentiation of haemopoietic stem cells. Atomkernenergie 14:235–236Google Scholar
  233. 229.
    Godwin HA, Zimmerman TS, Kimball HR, Wolff SM, Perry S (1968) Correlation of granulocyte mobilization with etiocholanolone and the subsequent development of myelosuppression in patients with acute leukemia receiving therapy. Blood 31:580–588PubMedGoogle Scholar
  234. 230.
    Goldberg JH, Friedman PA (1971) Antibiotics and nucleic acids. Annu Rev Biochem 60:775–810Google Scholar
  235. 231.
    Golde DW, Cline MJ (1975) Endotoxin-induced release of colony-stimulating activity in man. Prox Soc Exp Biol Med 194: 845–848Google Scholar
  236. 232.
    Goldie HJ, Price LA, Harrap KP (1972) Methotrexate toxicity: Correlation with duration of administration, plasma level, dose and excretion pattern. Eur J Cancer 8:409–414PubMedGoogle Scholar
  237. 233.
    Goldin A, Mantel N, Greenhouse SW, Venditti JM, Humphreys SR (1953) Estimation of the antileukemia potency of antimetabolite aminopterin administered alone and in combination with citrovorum factor or folinic acid. Cancer Res 13: 843–850PubMedGoogle Scholar
  238. 234.
    Goldman JM, Buskard NA, Th’ng KH (1976) Bone marrow culture in acute myeloid leukaemia. Lancet 2:260PubMedGoogle Scholar
  239. 235.
    Goodman JW, Hodgson GS (1962) Evidence for stem cells in the peripheral blood of mice. Blood 19:702–714PubMedGoogle Scholar
  240. 236.
    Gordon MY (1977) Changes in human bone marrow colony-forming cells following chemotherapy using an agar-diffusion chamber technique. In: Baum SJ, Ledney GD (eds) Experimental hematology today. Springer, Berlin Heidelberg New York, pp 233–237Google Scholar
  241. 237.
    Gordon MY, Blackett NM (1976) The sensitivities of human and murine hemopoietic cells exposed to cytotoxic drugs in an in vivo culture system. Cancer 36:2822–2826Google Scholar
  242. 238.
    Gordon MY, Douglas IDC (1976) Changes in proliferation rate of human bone marrow colony-forming cells measured by a cytosine arabinoside-diffusion chamber method. Eur J Cancer 12:551–555PubMedGoogle Scholar
  243. 239.
    Gordon MY, Douglas IDC (1977) The effects of busulphan, hydroxyurea and cytosine arabinoside on the colony-forming cells in chronic granulocytic leukaemic and nonleu-kaemic marrow. Leuk Res 1:71–73Google Scholar
  244. 240.
    Gordon MY, Douglas IDC (1977) The effect of peripheral blood contamination on colony yield from human bone marrow aspirates. Exp Hematol 5:274–280PubMedGoogle Scholar
  245. 241.
    Gordon MY, Blackett NM, Douglas IDC (1975) Colony formation by human haemopoietic precursor cells cultured in semi-solid agar in diffusion chamber. Br J Haematol 31:103–110PubMedGoogle Scholar
  246. 242.
    Gordon MY, Douglas IDC, Clink HM, Pickering BMJ (1976) Distribution of granulopoietic activity in the human skeleton, studied by colony growth in agar diffusion chambers. Br J Haematol 32: 537–542PubMedGoogle Scholar
  247. 243.
    Gottlieb JA, Drewinko B (1975) Review of the current clinical status of platinum coordination complexes in cancer chemotherapy. Cancer Chemother Rep 59:621–628PubMedGoogle Scholar
  248. 244.
    Gottlieb JA, Serpick AA (1971) Clinical evaluation of 5-(3,3-dimethyl-1-triazeno)-imid-azole-4-carboxamide in malignant melanoma or other neoplasms: Comparison of twice-weekly and daily administration schedules. Oncology 25:225–233PubMedGoogle Scholar
  249. 245.
    Graef I, Karnofsky DA, Jager VB, Krichesky B, Smith HW (1948) The clinical and pathologic effects of the nitrogen and sulfur mustards in laboratory animals. Am J Pathol 24:1–38PubMedGoogle Scholar
  250. 246.
    Graw RG Jr, Lohrmann H-P, Bull MI, Decter J, Herzig GP, Bull JM, Leventhal BG, Yankee RA, Herzig RH, Krueger GRF, Bleyer WA, Buja ML, McGinniss MH, Alter HJ, Whang-Peng J, Gralnick HR, Kirkpatrick CH, Henderson ES (1974) Bone-marrow transplantation following combination chemotherapy immunosuppression (B.A.C.T.) in patients with acute leukemia. Transplant Proc 6:349–354PubMedGoogle Scholar
  251. 247.
    Greenberg PL, Van Kersen I, Mosny S (1976) Cytotoxic effects of l-β-D-arabinofura-nosylcytosine and 6-thioguanine on granulocytic progenitor cells. Cancer Res 36:4412–4417PubMedGoogle Scholar
  252. 248.
    Gunz FW, Mani MK, Ravich RBM, Speden J, Vincent PC (1970) The use of etiocholanolone for the measurement of marrow granulocyte reserves. Med J Aust 1:763–767PubMedGoogle Scholar
  253. 249.
    Gupta RC, Robinson WA, Kurnick JE (1976) Felty’s syndrome: Effect of lithium on granulopoiesis. Ann J Med 61:29–32Google Scholar
  254. 250.
    Gutterman JU, Cardenas JO, Blumenschein GR, Hortobagyi G, Burgess MA, Livingston RB, Mavligit GM, Gottlieb JA, Freireich EJ, Hersh EM (1976) Chemoimmunotherapy of advanced breast cancer: Prolongation of remission and survival with BCG. Br Med J 2:1222–1225PubMedGoogle Scholar
  255. 251.
    Haas RJ, Fache I, Bonne F, Fliedner TM (1971) Die Wirkung von Hydroxyharnstoff auf die Hämopoiese der Ratte nach einmaliger oder fraktionierter Gabe. Arzneim Forsch 21:974–978Google Scholar
  256. 252.
    Haas RJ, Meyer-Hamme K, Fliedner TM (1972) The role of transplanted, slowly proliferating bone marrow cells for regeneration of lethally X-irradiated rat bone marrow. Scand J Haematol 9:121–129PubMedGoogle Scholar
  257. 253.
    Haas RJ, Rohruber W, Netzel B, Lau E (1979) Effects of CCNU on hematopoiesis in rats. Cancer Treat Rep 63:377–383PubMedGoogle Scholar
  258. 254.
    Hall SW, Valdivieso M, Benjamin RS (1977) Intermittent high single-dose ftorafur: Phase I clinical trial with a pharmacologic-toxicity correlation. Cancer Treat Rep 61:1495–1498PubMedGoogle Scholar
  259. 255.
    Halpern B, Biozzi G, Stiffel C, Mouton D (1966) Inhibition of tumour growth by administration of killed Corynebacterium parvum. Nature 212:853–854PubMedGoogle Scholar
  260. 256.
    Hambsch K, Otto W (1966) Die Beeinflussung des hämopoietischen Systems der weißen Ratte durch einen N-Lost-Cyclophosphamidester (ENDOXAN-ASTA). Folia Haematol (Leipz) 86:174–189Google Scholar
  261. 257.
    Hammond WP, Dale DC (1980) Lithium therapy of canine cyclic hematopoiesis. Blood 55:26–28PubMedGoogle Scholar
  262. 258.
    Hanks GE (1964) In vivo migration of colony-forming units from shielded bone marrow in the irradiated mouse. Nature 203:1393–1395PubMedGoogle Scholar
  263. 259.
    Hanks GE, Ainsworth EJ (1964) Endotoxin protection and colony-forming units. Radiat Res 32:367–382Google Scholar
  264. 260.
    Hansen HH, Selawry OS, Holland JF, McGall CB (1971) The variability of individual tolerance to methotrexate in cancer patients. Br J Cancer 25:298–305PubMedGoogle Scholar
  265. 261.
    Harbers E, Chaudhuri NK, Heidelberger C (1959) Studies on fluorinated pyrimidines. VIII. Further biochemical and metabolic investigations. J Biol Chem 234:1255–1262PubMedGoogle Scholar
  266. 262.
    Harding B, MacLennan JCM (1977) Myelotoxicity of methotrexate in animals with pyogenic infection. Br J Haematol 37:515–520PubMedGoogle Scholar
  267. 263.
    Harding B, Culvenor J, MacLennan ICM (1977) Effects of varying the interval between courses of methotrexate on its myelotoxic and anti-leukaemic properties. Br J Cancer 35:40–51PubMedGoogle Scholar
  268. 264.
    Harker WG, Rothstein G, Clarkson D, Athens JW, Macfarlane JL (1977) Enhancement of colony-stimulating activity production by lithium. Blood 49:263–267PubMedGoogle Scholar
  269. 265.
    Harriss EB, Aponte L (1968) The effect of nitrogen mustard on the hemopoietic stem cells of the bone marrow in the rat. Cell Tissue Kinet 1:289–298Google Scholar
  270. 265a.
    Hartsock RJ, Smith EB, Petty CS (1965) Normal variations with aging of the amount of hematopoietic tissue in bone marrow from the anterior iliac crest. Am J Clin Pathol 43:326–331PubMedGoogle Scholar
  271. 266.
    Haskill JS, McNeill TA, Moore MAS (1970) Density distribution analysis of in vivo and in vitro colony-forming cells in bone marrow. J Cell Physiol 75:167–180PubMedGoogle Scholar
  272. 267.
    Hattori K, Ino T (1977) Several cautions on the technique of bone marrow aspiration. In: Seno S, Takaku F, Irino S (eds) Topics in hematology. Excerpta Medica, Amsterdam Oxford, pp 1061–1064Google Scholar
  273. 268.
    Hayes FD, Short RD, Gibson JE (1972) A correlation between cyclophosphamide-in-duced leukopenia in mice and the presence of akylating metabolites. Proc Soc Exp Biol 139:417–421PubMedGoogle Scholar
  274. 269.
    Hayes DM, Cvitkovic E, Golbey RB, Schneider E, Helson E, Krakoff IH (1977) High dose cis-platinum diamine dichloride. Cancer 39:1372–1381PubMedGoogle Scholar
  275. 270.
    Heal JM, Fox PA, Doukas D, Schein PS (1978) Biological and biochemical properties of the 2-hydroxyl metabolites of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea. Cancer Res 38:1070–1074PubMedGoogle Scholar
  276. 271.
    Hedley DW, Millar JL, McElwain TJ, Gordon MY (1978) Acceleration of bone-marrow recovery by pre-treatment with cyclophosphamide in patients receiving high-dose melphalan. Lancet 2:966–967PubMedGoogle Scholar
  277. 272.
    Heidelberger C (1975) Fluorinated pyrimidines and their nucleosides. In: Sartorelli AC, Johnes DG (eds) Antineoplastic and immunosuppressive agents, Part II. Springer, Berlin Heidelberg New York (Handbook of experimental Pharmacology, vol 38, part 2, pp 193–231)Google Scholar
  278. 273.
    Heidelberger Ch, Chaudhuri NK, Danneberg P, Mooren D, Griesbach L (1957) Fluorinated pyrimidines, a new class of tumor-inhibitory compounds. Nature 179:663–666PubMedGoogle Scholar
  279. 274.
    Heit W, Kern P, Heimpel H, Kubanek B (1977) The role of granulocytes in colony stimulation by human white blood cells in agar cultures. Enhancement and inhibition of CSA. Scand J Haematol 18:105–112PubMedGoogle Scholar
  280. 275.
    Hellman S, Botnick LE (1977) Stem cell depletion: An explanation of the late effects of cytotoxins. Int J Radiat Oncol Biol Phys 2:181–184PubMedGoogle Scholar
  281. 276.
    Hellman S, Fink ME (1965) Granulocyte reserve following radiation therapy as studied by the response to a bacterial endotoxin. Blood 25:310–324PubMedGoogle Scholar
  282. 277.
    Hellman S, Grate HE (1971) X-Ray and alkylating agents alter differentiation of surviving hematopoietic stem cells. Blood 38:174–183PubMedGoogle Scholar
  283. 278.
    Hellman S, Grate HE (1971) Effect of cyclophosphamide on the murine hematopoietic stem cell compartment as measured by different assay techniques. Blood 38:706–714PubMedGoogle Scholar
  284. 279.
    Hellman S, Hannon E (1976) Effects of adriamycin on the radiation response of murine hematopoietic stem cells. Radiat Res 67:162–167PubMedGoogle Scholar
  285. 280.
    Hellman S, Grate HE, Chaffey JT, Carmel R (1970) Hematopoietic stem cell compartment: Patterns of differentiation following radiation or cyclophosphamide. In: Stolman F Jr (ed) Hemopoietic cellular proliferation. Grune & Stratton, New York, pp 49–55Google Scholar
  286. 281.
    Hellman S, Botnick LE, Hannon EC, Vigneulle RM (1978) Proliferative capacity of murine hematopoietic stem cells. Proc Natl Acad Sci USA 75:490–494PubMedGoogle Scholar
  287. 282.
    Hendry JH, Lajtha LG (1972) The response of hemopoietic colony-forming units to repeated doses of X-rays. Rad Res 52:309–315Google Scholar
  288. 283.
    Hildebrand J, Badjou R, Collard-Ronge E, Delforge A, Malarme M, Spiro T, Sztern B, Vandensteene A, Stryckmans PA (1980) Treatment of brain gliomas with high doses of CCNU and autologous bone marrow transplantation. Biomedicine 32:71–75PubMedGoogle Scholar
  289. 284.
    Hill JM, Loeb E, McLellan A, Hill NO, Amanullah K, King JJ (1975) Clinical studies of platinum coordination compounds in the treatment of various malignant diseases. Cancer Chemother Rep 59:647–659PubMedGoogle Scholar
  290. 285.
    Hillcoat BL, Banerjee M, McCulloch PB, Williams CKO (1977) Prediction of marrow toxicity in patients treated by intravenous infusion of 5-fluorouracil. Eur J Cancer 13:81–87PubMedGoogle Scholar
  291. 286.
    Hodgson G, Blackett N (1977) In vivo synchronisation of haemopoietic stem cells with hydroxyurea. Exp Hematol 5:423–426PubMedGoogle Scholar
  292. 287.
    Hodgson GS, Bradley TR (1979) Properties of haematopoietic stem cells surviving 5-fluorouracil treatment: Evidence for a pre-CFU-S cell? Nature 281:381–382PubMedGoogle Scholar
  293. 288.
    Hodgson GS, Bradley TR, Martin RF, Sumner M, Fry P (1975) Recovery of proliferating haemopoietic progenitor cells after killing by hydroxyurea. Cell Tissue Kinet 8:51–60PubMedGoogle Scholar
  294. 289.
    Hopkins HA, Kovacs CJ, Looney WB, Wakefield JA (1976) Differential recovery of intestine, bone marrow, and thymus of rats with solid tumors following 5-fluorouracil administration. Cancer Biochem Biophys 1:303–312PubMedGoogle Scholar
  295. 290.
    Hopkins HA, Looney WB, Wakefield JA, Morris HP, MacLeod MS (1978) The kinetics of host and experimental solid tumor responses after adriamycin. Br J Cancer 37:1006–1014PubMedGoogle Scholar
  296. 291.
    Høst H (1966) Regeneration of bone marrow cells in rats following cyclophosphamide or total body irradiation. Acta Radiol Ther Phys Biol 4: 337–352PubMedGoogle Scholar
  297. 292.
    Høst H (1966) Comparative effects of cyclophosphamide, nitrogen mustard, and total-body irradiation on survival and on white blood cells in rats. Radiat Res 27:638–651PubMedGoogle Scholar
  298. 293.
    Høst H (1966) Effect of intermittent hypoxia on regeneration of haematopoiesis in rats treated with cyclophosphamide or total body irradiation. Scand J Haematol 3:193–204PubMedGoogle Scholar
  299. 294.
    Hrsak J, Pavicic S (1974) Comparison of the effects of 5-fluorouracil and ftorafur on the haematopoiesis in mice. Biomedicine 21:164–167PubMedGoogle Scholar
  300. 295.
    Hryniuk WM (1972) Purineless death as a link between growth rate and cytotoxicity by methotrexate. Cancer Res 32:1506–1511PubMedGoogle Scholar
  301. 296.
    Humphrey EW, Hymes AC, Ansman RK, Ferguson DJ (1961) An evaluation of actinomycin D and mitomycin C in patients with advanced cancer. Surgery 50:881–885PubMedGoogle Scholar
  302. 297.
    Huybrechts M, Symann M, Trouet A (1979) Effects of daunorubicin and doxorubicin free and associated with DNA, on hemopoietic stem cells. Cancer Res 39:3738–3743PubMedGoogle Scholar
  303. 298.
    Iscove NN, Till JE, McCulloch EA (1970) The proliferative states of mouse granulopoietic progenitor cells. Proc Soc Exp Biol Med 134:33–36PubMedGoogle Scholar
  304. 299.
    Israels LG, Sinclair C, Graf J, Zipursky A (1962) Comparative effects of nitrogen mustard (HN2), chlorambucil (CB 1348), and busulfan (myleran) on the peripheral blood and the ferrokinetic patterns in dogs. Can J Biochem Physiol 40: 667–677Google Scholar
  305. 300.
    Itoga T, Laszlo J (1962) Döhle bodies and other granulocytic alterations during chemotherapy with cyclophosphamide. Blood 20:668–674PubMedGoogle Scholar
  306. 301.
    Jacobson LO, Spurr CL, Barron ES, Smith T, Lushbaugh C, Dick GF (1946) Nitrogen mustard therapy. Studies on the effect of metyhl-bis-(β-chloroethyl)amine hydrochloride on neoplastic diseases and allied disorders of the hemopoietic system. J Am Med Ass 132:263–271Google Scholar
  307. 302.
    Jacobson LO, Marks EK, Gaston E, Block MH (1949) The effects of nitrogen mustard on induced erythroblastic hyperplasia in rabbits. J Lab Clin Med 34: 902–924PubMedGoogle Scholar
  308. 303.
    Janssen PAJ (1976) The levamisole story. In: Jucker E (ed) Progress in research 20. Birkhäuser, Basel Stuttgart, p 347Google Scholar
  309. 304.
    Jenkins VK, Costanzi JJ, Ellis HN (1976) Effects of single and combined chemother-apeutic agents on hemopoietic stem cells in mice. Am J Hematol 1: 79–88PubMedGoogle Scholar
  310. 305.
    Jensen RH, Sharp JG, Zajic GH, Anderson RW (1977) Inverse relationship between splenomegaly and stem cell compartment size in mice treated with nitrogen mustard. Scand J Haematol 18:309–316PubMedGoogle Scholar
  311. 306.
    Johnson RK, Garbjanian BT, Houchens DP, Kline J, Gaston MR, Syrkin AB, Goldin A (1976) Comparison of 5-fluorouracil and ftorafur. I. Quantitative and qualitative differences in toxicity to mice. Cancer Treat Rep 60:1335–1345PubMedGoogle Scholar
  312. 306a.
    Jones BC, Radley JM, Bradley TR, Hodgson GS (1980) Enhanced megakaryocyte repopulating ability of stem cells surviving 5-fluorouracil treatment. Exp Hematol 8:61–64PubMedGoogle Scholar
  313. 307.
    Jones SE, Salmon SE (1979) Adjuvant therapy of cancer II. Grune & Stratton, New YorkGoogle Scholar
  314. 308.
    Josvasen N, Bøyum A (1973) Haematopoiesis in busulphan-treated mice. A comparison between two different stem cell assays. Scand J Haematol 11:78–86PubMedGoogle Scholar
  315. 309.
    Joyce RA, Chervenick PA (1977) Corticosteroid effect on granulopoiesis in mice after cyclophosphamide. J Clin Invest 60:277–283PubMedGoogle Scholar
  316. 310.
    Joyce RA, Chervenick PA (1979) Lithium effect on granulopoiesis following vinblastine (Abstr). Clin Res 27:388AGoogle Scholar
  317. 311.
    Joyce RA, Hartmann O, Chervenick PA (1979) Splenic granulopoiesis in mice following administration of cyclophosphamide. Cancer Res 39:215–218PubMedGoogle Scholar
  318. 312.
    Kaboth W, Trepel F, Schick P, Wernekke G, Begemann H (1968) Morphologische und funktionelle Veränderungen im Blutzellsystem des Meerschweinchens nach Behandlung mit cytostatischen Substanzen und Prednisolon. Z Gesamte Exp Med 148:306–336PubMedGoogle Scholar
  319. 313.
    Karev NI, Blokkina NG, Vozny EK, Pershin MP (1972) Experience with ftorafur treatment in breast cancer. Neoplasma 19:347–350PubMedGoogle Scholar
  320. 314.
    Kaul M, Hudson G (1969) Recovery of haemopoiesis after cyclophosphamide. Acta Haematol 41:170–179PubMedGoogle Scholar
  321. 315.
    Kennedy BJ, Theologides A (1961) The role of 5-fluorouracil in malignant disease. Ann Intern Med 55:719–730PubMedGoogle Scholar
  322. 316.
    Kern P, Heimpel H, Heit W, Kubanek B (1977) Granulocytic progenitor cells in aplastic anemia. Br J Haematol 35:613–623PubMedGoogle Scholar
  323. 317.
    Killman S-A, Cronkite EP, Fliedner TM, Bond VP (1962) Mitotic indices of human bone marrow cells. I. Number and cytologic distribution of mitoses. Blood 19:743–750Google Scholar
  324. 318.
    Kindred JE (1949) The blood cells and the hemopoietic and other organs of dogs given intravenous injections of 2-chloroethyl vesicants. Arch Pathol 47:378–398Google Scholar
  325. 319.
    Kirkwood JM, Frei E III (1978) 5-Fluorouracil (FU) with thymidine (TdR): A phase I study. Proc Amer Ass Cancer Res 19:159Google Scholar
  326. 320.
    Kociba RJ, Sleight SD (1971) Acute toxicologic and pathologic effects of cis-diamine dichloroplatinum (NSC-119875) in male rats. Cancer Chemother Rep 55:1–8PubMedGoogle Scholar
  327. 321.
    Koizumi S, Yamagami M, Veno Y, Miura M, Taniguchi N (1980) Resistance of human bone marrow CFU-C to high-dose methotrexate cytotoxicity. Exp Hematol 8:635–640PubMedGoogle Scholar
  328. 322.
    Kolb HJ, Storb R, Weiden PL, Ochs HD, Kolb H, Graham TC, Floersheim GL, Thomas ED (1974) Immunologic, toxicologic and marrow transplantation studies in dogs given dimethyl myleran. Biomedicine 20:341–352PubMedGoogle Scholar
  329. 323.
    Korn AP, Henkelman RM, Ottensmeyer FP, Till JE (1973) Investigations of a stochastic model of haemopoiesis. Exp Hematol 1:362–375PubMedGoogle Scholar
  330. 324.
    Korte W, Bredebach H (1967) Operation and hochdosierte zytostatische Behandlung (1,5 g bis 5,0 g pro Stoß) beim Ovarialkarzinom. Fortschr Med 85:299–304Google Scholar
  331. 325.
    Kovach JS, Moertel CG, Schutt AJ, Reitemeier RG, Hahn RG (1973) Phase II study of cis-diaminedichloroplatinum (NSC-119875) in advanced carcinoma of the large bowel. Cancer Chemother Rep 57:357–359PubMedGoogle Scholar
  332. 326.
    Krakoff IH, Lippman AJ (1974) Clinical trials of cis-platinum (II) diaminedichloride (PDD) in patients with advanced cancer. In: Connors TA, Roberts JJ (eds) Platinum coordination complexes in cancer chemotherapy. Springer, Berlin Heidelberg New York Recent Results in Cancer Research, vol 48, pp 183–190Google Scholar
  333. 327.
    Kubanek B, Bock E, Bock O, Heit W (1975) Growth patterns of foetal hemopoiesis after injury. In: Nakao K, Fisher JW, Takaku F (eds) Erythropoiesis. Proceedings of the Fourth International Conference on Erythropoiesis. University of Tokyo Press, Tokyo, pp 371–379Google Scholar
  334. 328.
    Kubanek B, Bock O, Heit W, Bock E, Harriss EB (1973) Size and proliferation of stem cell compartments in mice after depression of erythropoiesis. In: Wolstenholme GEW, O’Connors M (eds) Hemopoietic stem cells, Ciby Foundation Symposium 13. Amsterdam, Associated Scientific Publishers, p. 243–262Google Scholar
  335. 329.
    Kühböck J, Pietschmann H, Rothenbuchner G (1967) Untersuchungen des menschlichen Knochenmarkes unter Vinblastinsulfatwirkung. Folia Haematol (Leipz) 87:220–229Google Scholar
  336. 330.
    Kühböck J, Peitschmann H, Rothenbuchner G (1971) Klinische Erfahrungen mit Vinblastinsulfat. Wien Klin Wochenschr 83:185–188PubMedGoogle Scholar
  337. 331.
    Kurland J, Moore MAS (1977) Modulation of hemopoiesis by prostaglandins. Exp Hematol 5:357–373PubMedGoogle Scholar
  338. 332.
    Kurland JI, Bockman RS, Broxmeyer HE, Moore MAS (1978) Limitation of excessive myelopoiesis by the intrinsic modulation of macrophage-derived prostaglandin E. Science 199:552–555PubMedGoogle Scholar
  339. 333.
    Ladisch SL, Poplack DG, Bull JM (1978) Acceleration of myeloid recovery from cyclophosphamide-induced leukopenia by pretreatment with bacillus Calmette-Guérin. Cancer Res 38:1049–1051PubMedGoogle Scholar
  340. 334.
    Ladisch SL, Reaman GH, Poplack DG (1979) Bacillus Calmette-Guérin enhancement of colony stimulating activity and myeloid colony formation following administration of cyclophosphamide. Cancer Res 39:2544–2546PubMedGoogle Scholar
  341. 335.
    Lahiri SK (1976) Kinetics of haemopoietic recovery in endotoxin-treated mice. Cell Tissue Kinet 9:31–39PubMedGoogle Scholar
  342. 336.
    Lajtha LG (1970) Stem cell kinetics. In: Gordon AS (ed) Regulation of hematopoiesis; vol 1: Red cell production. Appleton Century Crofts, New York, pp 111–131Google Scholar
  343. 337.
    Lajtha LG, Schofield R (1974) On the problem of differentiation in haemopoiesis. Differentiation 2:313–320Google Scholar
  344. 338.
    Lampert F (1967) Morphologische und quantitativ-cytochemische Veränderungen der normalen menschlichen Knochenmarkszellen durch Cytostatika. Z Gesamte Exp Med 111:189–202Google Scholar
  345. 339.
    Lee Ch, Castles TR, Kinter LD (1973) Single-dose toxicity of cyclophosphamide (NSC-26271) in dogs and monkeys. Cancer Chemother Rep 4:51–71Google Scholar
  346. 340.
    Lee M, Durch S, Dale D, Finch C (1979) Kinetics of tumor-induced murine neutrophilia. Blood 53:619–632PubMedGoogle Scholar
  347. 341.
    Lee MY, Sperlin A, Dale DC (1980) Distribution of granulocytopoietic committed stem cells in mice with tumor-induced neutrophilia. Exp Hematol 8:249–255PubMedGoogle Scholar
  348. 342.
    Lempert N, Leather RP, Scharfman WB (1963) Methods of altering nitrogen mustard toxicity in dogs. I. Spleen and mesenteric artery exclusion. Blood 21:213–220PubMedGoogle Scholar
  349. 343.
    Levitt LJ, Questenberry PJ (1980) Effect of lithium on murine hematopoiesis in a liquid culture system. New Engl J Med 302:713–719PubMedGoogle Scholar
  350. 344.
    Levitt M, Mosher MS, DeConti RC (1973) Improved therapeutic index of methotrexate. Cancer Res 33:1729–1834PubMedGoogle Scholar
  351. 345.
    Lichtman MA, Weed RJ (1972) Alteration of the cell periphery during granulocyte maturation: Relationship to cell function. Blood 39: 301–316PubMedGoogle Scholar
  352. 346.
    Liss RH, Chadwick M (1974) Correlation of 5-fluorouracil (NSC-19893) distribution in rodents with toxicity and chemotherapy in man. Cancer Chemother Rep 58:777–786PubMedGoogle Scholar
  353. 347.
    LoBue J (1973) Stem cell and neutrophilic granulocyte kinetics. Med Clin North Am 57:265–287PubMedGoogle Scholar
  354. 348.
    Lohrmann H-P (1978) Thymidine-suicide of human granulocytic progenitor cells (CFU-C), Biomedicine 28:319–323PubMedGoogle Scholar
  355. 349.
    Lohrmann H-P (1979) Das Reaktionsmuster der normalen menschlichen Granulopoiese auf zytostatische Chemotherapie. Habilitationsschrift, Universität UlmGoogle Scholar
  356. 349a.
    Lohrmann H-P (1979) Tolerance of hemopoiesis for repeated cytotoxic drug therapy. Blut 39:237–244PubMedGoogle Scholar
  357. 350.
    Lohrmann H-P, Schreml W (1979) Sensitivity of human granulopoiesis in vitro to adriamycin before and after exposure in vivo. Cancer Res 39:527–530PubMedGoogle Scholar
  358. 351.
    Lohrmann H-P, Schreml W, Fliedner TM, Heimpel H (1977) Studies on blood granulocytic precursor cells (CFU-C) following high-dose chemotherapy in man. Exp Hematol [Suppl 2] 5: 95Google Scholar
  359. 352.
    Lohrmann H-P, Hansi W, Heimpel H (1978) Human placenta-conditioned medium for stimulation of human granulopoietic precursor cell (CFU-C) colony growth in vitro. Blut 36:81–88PubMedGoogle Scholar
  360. 353.
    Lohrmann H-P, Schreml W, Lang M, Betzler M, Fliedner TM, Heimpel H (1978) Changes of granulopoiesis during and after adjuvant chemotherapy of breast cancer. Br J Haematol 40:369–381PubMedGoogle Scholar
  361. 354.
    Lohrmann H-P, Schreml W, Fliedner TM, Heimpel H (1979) Reaction of human granulopoiesis to high-dose cyclophosphamide therapy. Blut 8:9–16Google Scholar
  362. 355.
    Looney WB, Macleod MS, Hopkins HA (1978) Solid tumor models for the assessment of different treatment modalities. VII. Single vs fractionated doses of 5-fluorouracil on two solid tumours and their hosts. Br J Cancer 37: 841–848PubMedGoogle Scholar
  363. 355a.
    Looney WB, Hopkins HA, Macleod MS (1979) Solid tumor models for the assessment of different treatment modalities. VIII. The scheduling of treatment for a chemotherapeu-tically resistant experimental solid tumor. Cancer 43:1201–1210PubMedGoogle Scholar
  364. 356.
    Lord BI (1975) Cell proliferation changes in hemopoietic tissue as a result of irradiation or drug administration: The control of cell proliferation in hemopoietic tissue. In: Nygaard OF, Adler HI, Sinclair WU (eds) Radiation research: Biomedical, chemical and physical perspectives. Academic Press, New York, pp 826–833Google Scholar
  365. 357.
    Lord BI (1976) Stem cell reserve and its control. In: Cairnie AB, Lala PK, Osmond DG (eds) Stem cells of renewing cell populations. Academic Press, New York, pp 165–179Google Scholar
  366. 358.
    Lord BI, Lajtha LG, Gidali J (1974) Measurement of the kinetic status of bone marrow precursor cells. Three cautionary tales. Cell Tissue Kinet 7: 507–515PubMedGoogle Scholar
  367. 359.
    Lord BI, Mori KJ, Wright EG (1977) A stimulator of stem cell proliferation in regenerating bone marrow. Biomedicine 27:223–226PubMedGoogle Scholar
  368. 360.
    Lord BI, Mori KJ, Wright EG, Lajtha LG (1976) An inhibitor of stem cell proliferation in normal bone marrow. Br J Haematol 34:441–445PubMedGoogle Scholar
  369. 361.
    Luce JK, Ihurman WG, Isaacs BL, Talley RW (1970) Clinical trials with the antitumor agent 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (NSC-45388). Cancer Chemother Rep 54:119–124PubMedGoogle Scholar
  370. 362.
    Lyman G, Williams CC, Preston D (1980) The use of lithium carbonate to reduce infection and leukopenia during systemic chemotherapy. N Engl J Med 302:257–260PubMedGoogle Scholar
  371. 363.
    MacVittie TJ (1979) Alterations induced in murine hemopoietic stem cells following a single injection of Corynebacterium parvum. In: Baum SJ, Ledney GD (eds) Experimental Hematology Today. Springer, New York Heidelberg Berlin, p 3Google Scholar
  372. 364.
    MacVittie TJ, Walker RI (1978) Endotoxin-induced alterations in canine granulopoiesis: Colony-stimulating activity, colony-forming cells in culture, and growth of cells in diffusion chambers. Exp Hematol 6:613–618PubMedGoogle Scholar
  373. 365.
    MacVittie TJ, Walker RI (1980) Hematologic responses induced by endotoxin in normal and endotoxin tolerant dogs. Exp Hematol 8:599–609PubMedGoogle Scholar
  374. 366.
    Maloney MA, Dorie MJ, Lamela RA, Roliers ZR, Patt HM (1978) Hematopoietic stem cell regulatory volumes as revealed in studies of the bgJ/bgJ: W/Wv chimera. J Exp Med 147:1189–1197PubMedGoogle Scholar
  375. 367.
    Marsh JC (1976) The effects of cancer chemotherapeutic agents on normal hematopoietic precursor cells: A review. Cancer Res 36:1853–1882PubMedGoogle Scholar
  376. 368.
    Marsh JC (1979) Comparison of the sensitivities of human, canine, and murine hematopoietic procursor cells to adriamycin and N-trifluoro-acetyladriamycin-14-valerate. Cancer Res 39:360–364PubMedGoogle Scholar
  377. 369.
    Martini H, Scheef W, Knecht W (1967) Verträglichkeit und Wirkung sehr hoch dosierter Endoxanstöße in der Tumortherapie. Med Welt 18:1573–1578Google Scholar
  378. 370.
    Massa G, Saviane A, Bogliolo G, Mitra G, Pannacciulli I (1977) Effetti des salasso sulla suscettibilita delle CFU-S di topi C57Bl/C3H a vari antiblastici. Boll Soc Ital Biol Sper 53:1252–1256PubMedGoogle Scholar
  379. 371.
    Massa G, Saviane A, Bogliolo G, Pannacciulli I (1976) Confronti die effetti di alchilanti, di antimetaboliti, e di antiblastici di altro tipo sulle CFU emopoietiche del topo. Boll Soc Ital Biol Sper 52:460–464PubMedGoogle Scholar
  380. 372.
    Mathé G, Amiel JL, Schwarzenberg L, Schneider L, Cattan A, Schlumberger JR, Hazart M, De Vassal F (1969) Active immunotherapy for acute lymphoblastic leukaemia. Lancet 1:697–699PubMedGoogle Scholar
  381. 373.
    Mathé G, Pouillart P, Lapeyraque F (1969) Active immunotherapy in L1210 leukaemia applied after the graft of tumour cells. Br J Cancer 23: 814–824PubMedGoogle Scholar
  382. 374.
    Mauro F, Briganti G, Elli R, Schiaffmi G, Zupi G (1976) Plateau phase cultures as a system for studying the effects of bleomycin in view of its utilization in vivo. Prog Bichem Pharmacol 11:93–106Google Scholar
  383. 375.
    McCulloch EA, Thompson NM, Siminovitch L, Till JE (1970) Effects of bacterial endotoxin on hemopoietic colony-forming cells in the spleens of normal mice and mice of genotype Sl/Sld. Cell Tissue Kinet 3:47–54PubMedGoogle Scholar
  384. 376.
    McElwain TJ, Hedley DW, Gordon MY, Jarman M, Millar JL, Pritchard J (1979) High dose melphalan and non-cryopreserved autologous bone marrow treatment of malignant melanoma and neuroblastoma. Exp Hematol [Suppl 5] 7:360–371Google Scholar
  385. 377.
    McNeill TA (1970) Antigenic stimulation of bone marrow colony-forming cells. III. Effect in vivo. Immunology 18:61–72PubMedGoogle Scholar
  386. 378.
    Metcalf D (1972) Effect of thymidine siuciding on colony formation in vitro by mouse hematopoietic cells. Proc Soc Exp Biol Med 139:511–514PubMedGoogle Scholar
  387. 379.
    Metcalf D (1977) Hemopoietic colonies. Springer, Berlin Heidelberg New York (Recent Results in Cancer Research, vol 61)Google Scholar
  388. 380.
    Metcalf D, Wilson JW (1976) Endotoxin-induced size change in bone marrow progenitors of granulocytes and macrophages. J Cell Physiol 89:381–392PubMedGoogle Scholar
  389. 381.
    Meyer LM, Fliedner TM, Cronkite EP (1964) Autologous bone-marrow transfusion following chemotherapy. Ann NY Acad Sci 114:499–508PubMedGoogle Scholar
  390. 382.
    Michaillow W, Mitrov GG, Zographov DG (1972) Über den Einfluß der Kombination von ionisierenden Strahlen und Cyclophosphamid auf die koloniebildenden hämopoietischen Stammzellen. Strahlentherapie 144:87–95Google Scholar
  391. 383.
    Micklem HS, Ogden DA (1976) Ageing of haematopoietic stem cell populations in the mouse. In: Cairnie AB, Lala PK, Osmond DG (eds) Stem cells of renewing cell populations. Academic Press, New York, pp 331–341Google Scholar
  392. 384.
    Micklem HS, Anderson N, Ross E (1975) Limited potential of circulating hemopoietic stem cells. Nature 256:41–43PubMedGoogle Scholar
  393. 385.
    Middleman E, Luce J, Frei E III (1971) Clinical trials with adriamycin. Cancer 28:844–850PubMedGoogle Scholar
  394. 386.
    Milenkovic P, Pavlovic-Kentera V (1980) Regeneration of erythroid committed precursor cells in polycythemic mice treated with cyclophosphamide. Exp Hematol 8:44–51PubMedGoogle Scholar
  395. 387.
    Millar JL, McElwain TJ (1978) Combinations of cytotoxic agents that have less than expected toxicity on normal tissues in mice. Antibiot Chemother 23:271–282PubMedGoogle Scholar
  396. 388.
    Millar JL, Hudspith BN, McElwain TJ, Phelps TA (1978) Effect of high-dose melphalan on marrow and intestinal epithelium in mice pretreated with cyclophosphamide. Br J Cancer 38:137–142PubMedGoogle Scholar
  397. 389.
    Millard RE, Blackett NM (1974) The recovery of haemopoietic progenitor cells in the mouse following cytotoxic agents. Br J Haematol 27:361–362PubMedGoogle Scholar
  398. 390.
    Millard RE, Okell SF (1975) The effect of cytosine arabinoside in vitro on agar colony-forming cells and spleen colony-forming cells of C57B1 mouse bone marrow. Cell Tissue Kinet 8:33–40PubMedGoogle Scholar
  399. 391.
    Millard RE, Blackett NM, Okell SF (1973) A comparison of the effect of cytotoxic agents on agar colony-forming cells, spleen colony-forming cells, and the erythrocytic repopulating ability of mouse bone marrow. J Cell Physiol 82: 309–317PubMedGoogle Scholar
  400. 392.
    Miller RC, Hill RB, Nichols WW, Meadows AT (1978) Acute and long-term cytogenetic effects of childhood cancer chemotherapy and radiotherapy. Cancer Res 38:3241–3246PubMedGoogle Scholar
  401. 393.
    Moertel CG, Reitemeier RJ, Hahn RG (1968) Therapy of advanced gastrointestinal cancer with l-3-bis-(2-chloroethyl)-l-nitrosourea (BCNU). Clin Pharmacol Ther 9:652–656PubMedGoogle Scholar
  402. 394.
    Moertel CG, Reitemeier RJ, Hahn RG, Schutt AJ (1970) Study of 5-(3.3-Dimethyl-l-tria-zeno)imidazole-4-carboxamide (NSC-45388) in patients with gastrointestinal carcinoma. Cancer Chemother Rep Part 1 54:471–473Google Scholar
  403. 395.
    Momparler RL, Karon M, Siegel SE, Avila F (1976) Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. Cancer Res 36:2891–2895PubMedGoogle Scholar
  404. 396.
    Monette FC, Gilio MJ, Chalifaux P (1974) Separation of proliferating CFU from G0 cells of murine bone marrow. Cell Tissue Kinet 7:443–450PubMedGoogle Scholar
  405. 397.
    Moore GE, Bross ID, Ausman R,Nadler S (1968) Effects of 5-fluorouracil (NSC-19893) in 389 patients with cancer. Cancer Chemother Rep 52: 641–653PubMedGoogle Scholar
  406. 398.
    Moore GE, DiPaolo J, Kondo T (1958) The chemotherapeutic effects and complications of actinomycin D in patients with advanced cancer. Cancer 11:1204–1214PubMedGoogle Scholar
  407. 399.
    Moore MAS, Williams N, Metcalf D (1973) In vitro colony formation by normal and leukemic human hematopoietic cells. Interaction between colony-forming and colony-stimulating cells. J Natl Cancer Inst 50:591–602PubMedGoogle Scholar
  408. 400.
    Morardet N, Parmentier C (1977) Description of a suicide technique in vitro for granulocytic stem cells (CFU) by hydroxyurea on normal human bone marrow. Biomedicine 27:349–353PubMedGoogle Scholar
  409. 401.
    Morley A, Blake J (1974) An animal model of chronic aplastic marrow failure. I. Late marrow failure after busulfan. Blood 44:49–56PubMedGoogle Scholar
  410. 402.
    Morley A, Blake J (1974) Haemopoietic precursor cells in experimental hypoplastic marrow failure. Aust J Exp Biol Med Sci 52:909–914PubMedGoogle Scholar
  411. 403.
    Morley A, Stohlman F Jr (1970) Cyclophosphamide-induced cyclical neutropenia. N Engl J Med 282:643–646PubMedGoogle Scholar
  412. 404.
    Morley A, Trainor K, Blake J (1975) A primary stem cell lesion in experimental chronic hypoplastic marrow failure. Blood 45:681–688PubMedGoogle Scholar
  413. 405.
    Morley A, Trainor K, Remes J (1976) Residual marrow damage: Possible explanation for idiosyncrasy to chloramphenicol. Br J Haematol 32:525–531PubMedGoogle Scholar
  414. 406.
    Morley AA, Trainor KJ, Seshadri RS (1978) Chronic hypoplastic marrow failure and residual injury. Blood Cells 4:253–266PubMedGoogle Scholar
  415. 407.
    Morse BS, Stohlman F Jr (1966) Regulation of erythropoiesis. XVIII. The effect of vincristine and erythropoietin on bone marrow. J Clin Invest 45:1241–1250PubMedGoogle Scholar
  416. 408.
    Morse BS, Rencricca NJ, Stohlman F Jr (1969) The effect of hydroxyurea on differentiated marrow erythroid precursors. Proc Soc Exp Biol Med 130:986–989Google Scholar
  417. 409.
    Morse BS, Rencricca NJ, Stohlman F Jr (1970) Relationship of erythropoietin effectiveness to the generative cycle of erythroid precursor cells. Blood 35:761–774PubMedGoogle Scholar
  418. 410.
    Morton DL, Eilber FR, Holmes EC, Hunt JS, Ketcham AS, Silverstein MJ, Sparks FS (1974) BCG-immunotherapy of malignant melanoma: Summary of a seven-year experience. Ann Surg 180:635–643PubMedGoogle Scholar
  419. 411.
    Müller-Nübling J, Fliedner TM (1979) Präklinische Untersuchungen über die Reaktion der Blut-CFU-C-Konzentration auf eine einmalige Applikation von Cyclophosphamid. Blut 38:175–179PubMedGoogle Scholar
  420. 412.
    Mullins GM, Colvin M (1975) Intensive cyclophosphamide (NSC-26271) therapy for solid tumors. Cancer Chemother Rep 59:411–419PubMedGoogle Scholar
  421. 413.
    Murphy DL, Goodwin FK (1971) Leukocytosis during lithium treatment. J Psychiatry 127:1559–1561Google Scholar
  422. 414.
    Myers CE, McGuire WP, Liss RH, Krim I, Grotzinger K, Young RC (1977) Adriamycin: The role of lipid peroxidation in cardiac toxicity and tumor response. Science 197:165–167PubMedGoogle Scholar
  423. 415.
    Nagourney RA, Fox P, Schein PS (1978) A comparison of the biological and biochemical properties of l-(4-amino-2-methylpyrimidin-5-yl)methyl-3-(2-chloroethyl)-3-nitrosourea and 2-[3-(2-chloroethyl)-3-nitrosoureido]-D-glucopyranose. Cancer Res 38:65–68PubMedGoogle Scholar
  424. 416.
    Nakayama M, Schuster J, Schoyerer W (1967) Klinische und tierexperimentelle Erfahrungen mit der Endoxan-Stoßtherapie. Dtsch Med Wochenschr 92:1915–1919PubMedGoogle Scholar
  425. 417.
    Nakeff A, McLellan WL, Bryan J, Valeriote FA (1979) Response of megakaryocyte, erythroid, and granulocyte-macrophage progenitor cells in mouse bone marrow to gamma-irradiation and cyclophosphamide. In: Baum SJ, Ledney GD (eds) Experimental Hematology Today 1979. Springer, New York Heidelberg Berlin, pp 99–104Google Scholar
  426. 418.
    Nasrallah AG, McGarry MP (1976) In vivo distinction between a target cell for Friend virus (FVP) and murine hematopoietic stem cells. J Natl Cancer Inst 57:443–445PubMedGoogle Scholar
  427. 419.
    Necas E, Neuwirt J (1976) Control of haemopoietic stem cell proliferation by cells in DNA synthesis. Br J Haematol 33:395–400PubMedGoogle Scholar
  428. 420.
    Necas E, Neuwirt J (1976) Proliferation rate of haemopoietic stem cells after damage by several cytostatic agents. Cell Tissue Kinet 9:479–487PubMedGoogle Scholar
  429. 421.
    Necas E, Neuwirt J (1977) Effect of hydroxyurea and vinblastine on the proliferation of the pluripotent stem cells. Neoplasma 24:29–40PubMedGoogle Scholar
  430. 422.
    Necas E, Ponka P, Neuwirt J (1978) Changes in stem cell compartments in mice after hydroxyurea. Cell Tissue Kinet 11: 119–127PubMedGoogle Scholar
  431. 423.
    Necas E, Ponka P, Neuwirt J (1978) Disappearance of haemopoietic stem cells from blood after hydroxyurea. Folia Biol (Praha) 24:78–90Google Scholar
  432. 424.
    Nesbit ME, Lowman JT (1969) Hematopoiesis and serum iron changes following vincristine sulfate. Blood 34:633–644PubMedGoogle Scholar
  433. 425.
    Niho Y, Till JE, McCulloch EA (1976) Effect of arabinosyl cytosine on granulopoietic colony formation by marrow cells from leukemic and non-leukemic patients. Exp Hematol 4:63–69PubMedGoogle Scholar
  434. 426.
    Ninkov V, Piletic O (1974) Hematopoietic response after treatment with cyclophosphamide and autotransplantation of non-damaged bone marrow cells. Acta Biol Med Ger 33:35–41PubMedGoogle Scholar
  435. 427.
    Niskanen E (1967) Bone marrow cell proliferation after busulphan treatment and its relation to humoral control mechanisms. Acta Pathol Microbiol Scand [Suppl 190] 70Google Scholar
  436. 428.
    Niskanen E, Rytömaa T, Kivilaakso E (1971) Reversion of the inhibitory effect of busulphan on bone marrow cell proliferation, by chlorambucil. Acta Pathol Microbiol Scand [A] 79:102–108Google Scholar
  437. 429.
    Nissen-Meyer R, Host H (1960) A comparison between the haematological side effects of cyclophosphamide and nitrogen mustard. Cancer Chemother Rep 9:51–55PubMedGoogle Scholar
  438. 430.
    Northup JD, Bull JM, Carbone PP (1972) Proliferative activity of human granulocytes, as estimated quantitatively by in vitro colony formation. J Natl Cancer Inst 48:629–637PubMedGoogle Scholar
  439. 430a.
    Nowrousian MR, Schaefer UW, Oehl S, Boecker WR, Schmidt CG (1980) Effekte der zytostatischen Langzeitchemotherapie mit Bleomycin auf die Hämatopoese (Abstr). Blut 41:320Google Scholar
  440. 431.
    Nye RN (1931) Bone marrow volume in rabbits. Proc Soc Exp Biol Med 29:34–37Google Scholar
  441. 432.
    O’Connell RA (1970) Leukocytosis during lithium carbonate treatment. Int J Pharmacopsychiatry 4:30–34Google Scholar
  442. 433.
    O’Donnell JF, McKoy WS, Makuch RW, Bull JM (1979) Increased in vitro toxicity to mouse bone marrow with l,3-(2-chloroethyl)-l-nitrosourea and hyperthermia. Cancer Res 39:2547–2549PubMedGoogle Scholar
  443. 434.
    Ogawa M, Bergsagel DE, McCulloch EA (1971) Differential effects of melphalan on mouse myeloma (adj. PC-5) and hemopoietic stem cells. Cancer Res 31:2116–2119PubMedGoogle Scholar
  444. 435.
    Ogawa M, Bergsagel DE, McCulloch EA (1973) Chemotherapy of mouse myeloma: Quantitative cell cultures predictive of response in vivo. Blood 41:7–15PubMedGoogle Scholar
  445. 436.
    Ogawa M, Bergsagel DE, McCulloch EA (1973) Sensitivity of human and murine hemopoietic precursor cells to chemotherapeutic agents assessed in cell culture. Blood 42:851–856PubMedGoogle Scholar
  446. 437.
    Ogawa M, Gale GR, Keirn SS (1975) Effect of cis-diamminedichloroplatinum (NSC 119875) on murine and human hemopoietic precursor cells. Cancer Res 35:1398–1401PubMedGoogle Scholar
  447. 438.
    Old LJ, Clarke DA, Benacerraf B (1959) Effect of bacillus Calmette-Guérin (BCG) infection on transplanted tumours in the mouse. Nature 184:291–292PubMedGoogle Scholar
  448. 439.
    Oliverio VT (1976) Pharmacology of the nitrosoureas: An overview. Cancer Treat Rep 60:703–707PubMedGoogle Scholar
  449. 440.
    Osband M, Cohen H, Cassady JR, Faffe N (1977) Severe and protracted bone marrow dysfunction following long-term therapy with methyl-CCNU. Proc Am Ass Cancer Res 18:303Google Scholar
  450. 441.
    Page PL, Cook PA, Greenberg HM, Hartwell BL, Robinson SH (1978) Cytotoxic reduction of murine marrow stem cells and subsequent recovery (Abstr.) Exp Hematol [Suppl 3] 6:68Google Scholar
  451. 441a.
    Page PL, Gerson SL, Hartwell BL, Robinson SH (1978) Chemotherapy-induced alterations in proliferative capacity of marrow stem cells (Abstr.) Clin Res 26:537AGoogle Scholar
  452. 442.
    Panasci LC, Fox PA, Schein PS (1977) Structure-activity studies of methylnitrosourea antitumor agents with reduced bone marrow toxicity. Cancer Res 37:3321–3328PubMedGoogle Scholar
  453. 443.
    Panasci LC, Green D, Schein PS (1979) Chlorozotocin. Mechanism of reduced bone marrow toxicity in mice. J Clin Invest 64:1103–1111PubMedGoogle Scholar
  454. 444.
    Pannacciulli I, Bogliolo G, Massa G, Ronco D, Fresco G, Saviane A, Dolocino G, Celle G (1975) Ricerca sperimentale sui rapporti tra attivazione eritropoietica ed emotossicità di alcuni antiblastici. Tumori 61:179–198PubMedGoogle Scholar
  455. 445.
    Pannacciulli I, Ghio R, Bigliolo G, Massa G, Saviane A, Bianchi G (1976) Cellule staminali emopoietiche ed antiblastici. 1. Variazioni delle cellule formatrici die colonie in vivo e in vitro dopo somministrazione in dose singola di ciclofosfamide, vinblastina e azatioprina. Haematologica 61:433–448Google Scholar
  456. 446.
    Pannacciulli IM, Massa G, Saviane AG, Bianchi G, Bogliolo GV, Ghio R (1977) The effects of chronic administration of cyclophosphamide on haemopoietic stem cells. Scand J Haematol 19:217–223PubMedGoogle Scholar
  457. 447.
    Papac RJ (1968) Clinical and hematologic studies with 1-β-D-arabinosylcytosine. J Natl Cancer Inst 40:997–1002PubMedGoogle Scholar
  458. 448.
    Parker LM, Hirst M, Israel M (1978) N-Trifluoroacetyladriamycin-14-valerate. Additional mouse antitumor and toxicity studies. Cancer Treat Rep 62:119–127PubMedGoogle Scholar
  459. 449.
    Parmentier C, Droz JP, Tubiana M (1978) Ways of expressing results of human bone marrow progenitor cell culture. Br J Haematol 40:105–109PubMedGoogle Scholar
  460. 450.
    Parmentier C, Maraninchi D, Morardet N, Droz JP (1978) Observations on the distribution of granulocytic progenitor cells (CFU-C) in human bone marrow: The importance of the manner in which the results of in vitro cultures are reported. Br J Haematol 40:353–354PubMedGoogle Scholar
  461. 451.
    Patt HM (1957) A consideration of myeloid-erythroid balance in man. Blood 12:777–787PubMedGoogle Scholar
  462. 452.
    Patt HM, Maloney MA (1972) Relationship of bone marrow cellularity and proliferative activity: A local regulatory mechanism. Cell Tissue Kinet 5: 303–309PubMedGoogle Scholar
  463. 453.
    Pegg DE (1963) The hematological side effects of cyclophosphamide and a discussion of autologous bone marrow grafting after cancer chemotherapy. Cancer Chemother Rep 27:39–44Google Scholar
  464. 454.
    Perez C, Sutow WW, Wang YM, Herson J (1979) Evaluation of overall toxicity of high-dosage methotrexate regimens. Med Pediatr Oncol 6:219–228PubMedGoogle Scholar
  465. 455.
    Philips FS, Sternberg SS, Schwartz HS, Cronin AP, Sodergren JE, Vidal PM (1967) Hydroxyurea. I. Acute cell death in proliferating tissues in rats. Cancer Res 27:61–74PubMedGoogle Scholar
  466. 456.
    Pike BL, Robinson WA (1970) Human bone marrow colony growth in agar gel. J Cell Physiol 76:77–84PubMedGoogle Scholar
  467. 457.
    Pinedo HM, Zaharko DS, Bull J, Chabner BA (1977) The relative contribution of drug concentration and duration of exposure to mouse bone marrow toxicity during continuous methotrexate infusion. Cancer Res 37:445–450PubMedGoogle Scholar
  468. 458.
    Pinedo HM, Zaharko DS, Bull JM, Chabner BA (1976) The reversal of methotrexate cytotoxicity to mouse bone marrow cells by leucovorin and nucleosides. Cancer Res 36:4418–4428PubMedGoogle Scholar
  469. 459.
    Pinedo HM, Zaharko DS, Chabner BA, Bull J (1976) Evidence for early recruitment of granulocyte precursors during high-dose methotrexate infusion in mice. Blood 48:301–307PubMedGoogle Scholar
  470. 460.
    Pliess G, Fassbender D (1961) Die Wirkung subletaler Dosen Endoxan auf die Hämopoese der Ratte. Arzneim Forschung 11:179–188Google Scholar
  471. 461.
    Pluznik DH, Sachs L (1965) The cloning of normal mast cells in tissue culture. J Cell Comp Physiol 66:319–324Google Scholar
  472. 462.
    Porteous DD, Lajtha LG (1966) On stem-cell recovery after irradiation. Br J Haematol 12:177–188PubMedGoogle Scholar
  473. 463.
    Pouillart P, Palangie T, Schwarzenberg L, Brugerie H, Lhéritier J, Mathé G (1976) Effect of BCG on hematopoietic stem cells: Experimental and clinical study. Cancer Immunol Immunother 1:163–169Google Scholar
  474. 464.
    Powles RL (1976) Immunotherapy in the management of acute leukaemia. Br J Haematol 32:145–149PubMedGoogle Scholar
  475. 465.
    Preisler HD, Henderson ES (1972) Effect of suppression of erythropoiesis on hematopoietic stem cells in the mouse. J Cell Physiol 79:103–110PubMedGoogle Scholar
  476. 466.
    Preisler HD, Henderson ES (1971) Effect of cytosine arabinoside and 1,3-bis(2-chloro-ethyl)-1-nitrosourea on hematopoietic precursors in the mouse. J Natl Cancer Inst 47:971–977PubMedGoogle Scholar
  477. 467.
    Quesenberry PJ, Morley A, Miller M, Rickard K, Howard D, Stohlman F Jr (1973) Effect of endotoxin on granulopoiesis and the in vitro colony-forming cell. Blood 41:391–398PubMedGoogle Scholar
  478. 468.
    Quesenberry PJ, Morley A, Ryan M, Howard D, Stohlman F Jr (1973) The effect of endotoxin on murine stem cells. J Cell Physiol 82:239–244PubMedGoogle Scholar
  479. 469.
    Quesenberry P, Morley A, Stohlman F Jr, Rickard K, Howard D, Smith M (1972) Effect of endotoxin on granulopoiesis and colony-stimulating factor. N Engl J Med 286:227–232PubMedGoogle Scholar
  480. 470.
    Quesenberry P, Zuckerman K, Ryan M, Stohlman F Jr (1977) A dichotomy between the release of bone marrow granulocytes and stem cells. Proc Soc Exp Biol Med 154:53–56Google Scholar
  481. 471.
    Radley JM, Scurfield G (1979) Effects of 5-fluorouracil on mouse bone marrow. Br J Haematol 43:341–351PubMedGoogle Scholar
  482. 472.
    Ragab AH, Gilkerson E, Myers M (1974) The effect of 6-mercaptopurine and allopurinol on granulopoiesis. Cancer Res 34:2246–2249PubMedGoogle Scholar
  483. 473.
    Ragab AH, Gilkerson E, Myers M, Choi SC (1974) The culture of colony-forming units from the peripheral blood and bone marrow of children with acute lymphocytic leukemia. Cancer 34:663–669PubMedGoogle Scholar
  484. 474.
    Randolph VL, Wittes RE (1978) Weekly administration of cis-diamminedichloroplatinum (II) without hydration or osmotic diuresis. Eur J Cancer 14:753–756PubMedGoogle Scholar
  485. 475.
    Razek A, Valeriote F, Vietti T (1972) Survival of hemopoietic and leukemic colony-forming cells in vivo following the administration of daunorubicin or adriamycin. Cancer Res 32:1496–1500PubMedGoogle Scholar
  486. 476.
    Reimer RR, Hoover R, Fraumeni JF, Young RC (1977) Acute leukemia after alkylating-agent therapy of ovarian cancer. N Engl J Med 297:177–180PubMedGoogle Scholar
  487. 477.
    Reissmann K, Ito K (1966) Selective eradication of erythropoiesis by actinomycin D as a result of interference with hormonally controlled effector pathway of cell differentiation. Blood 28:201–212PubMedGoogle Scholar
  488. 478.
    Reissmann K, Samorapoompichit S (1969) Effect of erythropoietin on regeneration of hematopoietic stem cell after 5-fluorouracil administration. J Lab Clin Med 73:544–550PubMedGoogle Scholar
  489. 479.
    Reissmann KR, Samorapoompichit S (1970) Effect of erythropoietin on proliferation of erythroid stem cells in the absence of transplantable colony-forming units. Blood 36:287–296PubMedGoogle Scholar
  490. 480.
    Reissmann KR, Udupa KB (1972) Effect of erythropoietin on proliferation of erythropoietin-responsive cells. Cell Tissue Kinet 5:481–489PubMedGoogle Scholar
  491. 481.
    Reissmann KR, Udupa KB, Kawada K (1974) Effects of erythropoietin and androgens on erythroid stem cells after their selective suppression by BCNU. Blood 44: 649–657PubMedGoogle Scholar
  492. 482.
    Reissmann K, Udupa KB, Okamura H (1970) Effect of endotoxin on normal and 5-fluorouracil-suppressed hemopoietic stem cells. J Lab Clin Med 76:652–658PubMedGoogle Scholar
  493. 483.
    Rich IN, Heit W, Kubanek B (1980) The effect of actinomycin D on hemopoiesis. I. Short-term effects. Blut 41:29–40PubMedGoogle Scholar
  494. 484.
    Richman CM, Weiner RS, Yankee RA (1976) Increase in circulating stem cells following chemotherapy in man. Blood 47:1031–1039PubMedGoogle Scholar
  495. 485.
    Rickard KA, Morley A, Howard D, Stohlman F Jr (1971) The in vitro colony-forming cell and the response to neutropenia. Blood 37:6–22PubMedGoogle Scholar
  496. 486.
    Rickard KA, Shadduck RK, Howard DE, Stohlman F Jr (1970) A differential effect of hydroxyurea on hemopoietic stem cell colonies in vitro and in vivo. Proc Soc Exp Biol Med 134:152–156Google Scholar
  497. 487.
    Rizzoli V, Jacobs S, Butturini U (1978) Selectivity in rescue of high-dose methotrexate. In: Periti P (ed) High-dose methotrexate: Pharmacology, toxicology, and chemotherapy. Editrice Giuntina, Florence (Chemioterapia Oncologica, Supplemento dicembre) pp 71–84Google Scholar
  498. 488.
    Robinson WA, Mangalik A (1975) The kinetics and regulation of granulopoiesis. Semin Hematol 12:7–25PubMedGoogle Scholar
  499. 489.
    Rojas AF, Mickiewicz E, Feierstein JN, Glait H, Olivari AJ (1976) Levamisole in advanced human breast cancer. Lancet 1:211–215PubMedGoogle Scholar
  500. 490.
    Rosenberg B, Van Camp L, Krigas T (1965) Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 205: 698–699PubMedGoogle Scholar
  501. 491.
    Rosenblum ML, Reynolds AF, Smith KA, Rumack BH, Walker MD (1973) Chloro-ethyl-cyclohexyl-nitrosourea (CCNU) in the treatment of malignant brain tumors. J Neurosurg 39:306–314PubMedGoogle Scholar
  502. 492.
    Rosendaal M, Hodgson GS, Bradley TR (1979) Organisation of haemopoietic stem cells: The generation-age hypothesis. Cell Tissue Kinet 12:17–29PubMedGoogle Scholar
  503. 493.
    Rosenoff SH, Bull JM, Young RC (1975) The effect of chemotherapy on the kinetics and proliferative capacity of normal and tumorous tissues in vivo. Blood 45:107–118PubMedGoogle Scholar
  504. 494.
    Rosenhoff SH, Bostick F, Young RC (1975) Recovery of normal hematopoietic tissue and tumor following chemotherapeutic injury from cyclophosphamide (CTX): Comparative analysis of biochemical and clinical techniques. Blood 45:465–475Google Scholar
  505. 495.
    Rossof AH, Slayton RE, Perlia CP (1972) Preliminary clinical experience with cis-diamminodichloroplatinum (II) Cancer 30:1451–1456PubMedGoogle Scholar
  506. 496.
    Rothstein G, Clarkson DR, Larsen W, Grosser BI, Athens JW (1978) Effect of lithium on neutrophil mass and production. N Engl J Med 298:178–180PubMedGoogle Scholar
  507. 497.
    Salasoo S, Freedman A (1978) Prevention of methotrexate toxicity: Effect of infusion rate on clearance. In: Periti (ed) High-dose methotrexate: Pharmacology, toxicology, and chemotherapy. Editrice Giuntina, Firenze (Chemoterapia oncologica Supplemento dicembre) 1978, pp 163–172Google Scholar
  508. 498.
    Santelli G (1977) Potentiation of 5-fluorouracil cytotoxicity by thymidine against leukemia cells. Proc Am Assoc Cancer Res and Amer Soc Clin Oncol 18:148Google Scholar
  509. 499.
    Santelli G, Valeriote F (1978) In vivo enhancement of 5-fluorouracil cytotoxicity to AKR leukemia cells by thymidine in mice. J Natl Cancer Inst 61:843–847PubMedGoogle Scholar
  510. 500.
    Santos GW, Tutschka PJ (1974) Marrow transplantation in the busulfan-treated rat: Preclinical model of aplastic anemia. J Natl Cancer Inst 53:1781–1785PubMedGoogle Scholar
  511. 501.
    Saviane A, Massa G, Bogliolo G, Pannacciulli I (1976) L’azione die antiblastia ciclo-spezifici e non ciclo spezifici scelle CFU emopoietiche del topo depo salasso. Boll Soc Ital Biol Sper 52:465–468PubMedGoogle Scholar
  512. 502.
    Scaro JL, Alvarez Prado de Tombolesi AR, Guidi EE (1970) Effect of actinomycin D on the erythropoietic restoring capacity of mouse bone marrow cells. Acta physiol Lat Am 20:265–270PubMedGoogle Scholar
  513. 503.
    Scaro JL, Rendo MEB, De Tombolesi ARAP (1972) Hematopoietic recovery after a single high dose of cyclophosphamide in the mouse. Acta physiol Lat Am 22:258–265PubMedGoogle Scholar
  514. 504.
    Scaro JL, Rendo ME, Buys MC, Zenteno A (1973) Studies on hemopoietic stem cell kinetics after a single high dose of actinomycin D (AM), cyclophosphamide (CY) and busulphan (BU) in the mouse. Acta physiol Lat Am 23:548–550PubMedGoogle Scholar
  515. 505.
    Schaefer UW, Nowrousian MR, Öhl S, Boecker WR, Scheulen ME, Schilcher B, Schmidt CG (1980) Autologous bone marrow transplantation. The influence of prolonged cytotoxic chemotherapy. In: Thierfelder S, Rodt H, Kolb HJ (eds) Immunobiology of bone marrow transplantation. Springer, Berlin Heidelberg New York, pp 275–283Google Scholar
  516. 506.
    Schaeppi U, Heyman IA, Fleischman RW, Rosenkrantz H, Ilievski V, Phelan R, Cooney DA, Davis RD (1973) cis-Dichlorammineplatinum (II) (NSC-119875): Preclinical toxicologic evaluation of intravenous injection in dogs, monkeys, and mice. Toxicol Appl Pharmacol 25:230–241PubMedGoogle Scholar
  517. 507.
    Schein PS, Winokur SH (1975) Immunosuppressive and cytotoxic chemotherapy: Long-term complications. Ann Intern Med 82:84–95PubMedGoogle Scholar
  518. 508.
    Schein PS, Bull JM, Doukas D, Hoth D (1978) Sensitivity of human and murine hematopoietic precursor cells to 2-[3-(2-chloroethyl)-3-nitrosoureido]-D-glucopyranose and 1,3-bis(2-chloroethyl)-l-nitrosourea. Cancer Res 38:257–260PubMedGoogle Scholar
  519. 509.
    Schick P, Trepel F, Begemann H (1968) Morphologische und funktionelle Veränderungen im Blutzellsystem des Meerschweinchens nach Behandlung mit cytostatischen Substanzen, Prednisolon und Phenylbutazon. Z Gesamte Exp Med 148:275–305PubMedGoogle Scholar
  520. 510.
    Schneider R (1962) Vergleichende Untersuchungen über die Wirksamkeit einiger Zytostatika und der Röntgenbestrahlung. Strahlentherapie 119:104–110Google Scholar
  521. 511.
    Schneider R (1965) Beitrag zur Wirkungsweise einiger Zytostatika und ionisierender Strahlen. 1. Teil: Morphologische und funktionelle Untersuchungen von Knochenmark und Milz normaler Inzuchtratten ohne Impftumoren. Strahlentherapie 126:213–235PubMedGoogle Scholar
  522. 512.
    Schofield R (1978) The relationship between the spleen colony-forming cell and the haemopoietic stem cell. A hypothesis. Blood Cells 4:7–25PubMedGoogle Scholar
  523. 513.
    Schreml W, Betzler M, Lang M, Lohrmann H-P, Kubitza P, Schlag P, Flad H-D, Herfarth Ch, Heimpel H (1980) Adjuvant intermittent chemo-immuno-therapy of breast cancer. In: Mouridsen HT, Palshof T (eds) Breast cancer, experimental and clinical aspects. Pergamon Press, Oxford New York, pp 165–168Google Scholar
  524. 514.
    Schreml W, Bock O, Bock E, Heit W, Kubanek B (1974) Different action of suicidal doses of tritiated thymidine and hydroxyurea on murine haemopoietic cells. Cell Tissue Kinet 7:517–527PubMedGoogle Scholar
  525. 515.
    Schreml W, Lohrmann H-P (1979) No effects of levamisole on cytotoxic drug-induced changes of human granulopoiesis. Blut 38:331–336PubMedGoogle Scholar
  526. 516.
    Schreml W, Lohrmann H-P (1979) Effect of high-dose methotrexate with citrovorum factor on human granulopoiesis. Cancer Res 39:4195–4199Google Scholar
  527. 517.
    Schreml W, Lohrmann H-P (1979) Hematotoxicity of adjuvant therapy. In: Jones SE, Salmon SE (eds) Adjuvant therapy of cancer II. Grune & Stratton, New York, pp 63–70Google Scholar
  528. 517a.
    Schreml W, Lohrmann H-P (1981) Effect of two nitrosoureas (methyl-CCNU, BCNU) with 5-fluorouracil upon the human granulopoietic system. In: Serrou B, Schein PS, Imbach J-L (eds) Nitrosoureas in Cancer Treatment. Elsevier/North Holland, Amsterdam, p 207–213Google Scholar
  529. 518.
    Schubert JCF, Fischer M, Hilbert L (1969) Erfahrungen mit „ultrahohen“ Cyclophos-phamid-Dosen an 42 Kranken mit soliden und lymphoretikulären Tumoren. Dtsch Med Wochenschr 94:2583–2592PubMedGoogle Scholar
  530. 519.
    Schutt AJ, Hahn RG, Reitemeier RJ, Moertel CG (1973) A phase 2 study of intermittent high-dose cyclophosphamide therapy of advanced gastrointestinal cancer. Cancer Res 33:2218–2220PubMedGoogle Scholar
  531. 520.
    Schwartz PM, Dunigan JM, Marsh JC, Handschumacher RE (1980) Allopurinol modification of the toxicity and antitumor activity of 5-fluorouracil. Cancer Res 40:1885–1889PubMedGoogle Scholar
  532. 521.
    Scott MT (1974) Corynebacterium parvum as an immunotherapeutic anti-cancer agent. Semin Oncol 1: 367–378PubMedGoogle Scholar
  533. 522.
    Seidel HJ (1977) Hematologic effects of a single dose of methylnitrosourea. Exp Hematol 5:19–26PubMedGoogle Scholar
  534. 523.
    Seidel HJ, Kreja L (1980) Erythroid stem cell regeneration in normal and plethoric mice treated by cytosinarabinoside. Exp Hematol 8:541–548PubMedGoogle Scholar
  535. 524.
    Seidel H-J, Opitz U (1979) Effect of actinomycin D and busulphan on stem cells in normal and Friend virus-infected mice. Blut 38:349–360PubMedGoogle Scholar
  536. 525.
    Seidel H-J, Opitz U (1979) Hematopoietic stem cells in Friend murine leukemia virus-infected mice undergoing chemotherapy: Remission and relapse of erythropoie-tin-indepedent erythropoiesis induced by hydroxyurea. J Natl Cancer Inst 62:531–536PubMedGoogle Scholar
  537. 526.
    Seidel H-J, Opitz U (1979) Erythroid stem cell regeneration in normal and plethoric mice treated with hydroxyurea. Exp Hematol 7:500–508PubMedGoogle Scholar
  538. 527.
    Seifert P, Baker LH, Reed ML, Vaitkevicius VK (1975) Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 36:123–128PubMedGoogle Scholar
  539. 528.
    Senn JS, McCulloch EA (1970) Kinetics of regeneration after cyclophosphamide in human marrow assessed by a cell culture method (Abstr). Exp Hematol 20:8–9Google Scholar
  540. 529.
    Sensenbrenner LL, Owens AH (1967) The effects of mechlorethamine on bone marrow function and iron metabolism in man. Hopkins Med J 121:162–174Google Scholar
  541. 530.
    Sensenbrenner LL, Owens AH Jr, Zawatzsky LS, Elfenbein G (1972) The comparative effects of selected cytotoxic agents on transplanted hematopoietic cells. Transplantation 14:347–351PubMedGoogle Scholar
  542. 531.
    Sensenbrenner LL, Owens AH, Heiby JR, Jeejeebhoy HF (1973) Comparative effects of cytotoxic agents on transplanted hematopoietic and antibody-producing cells. J Natl Cancer Inst 50:1027–1033PubMedGoogle Scholar
  543. 532.
    Sensenbrenner LL, Marini JJ, Colvin M (1979) Comparative effects of cyclophosphamide, isophosphamide, 4-methylcyclophosphamide, and phosphor amide mustard on murine hematopoietic and immunocompetent cells. J Natl Cancer Inst 62:975–981PubMedGoogle Scholar
  544. 533.
    Sharp JG, Thomas DB (1971) The effects of mustine hydrochloride on the colony-forming units of murine bone marrow. Acta Haematol 46:271–274PubMedGoogle Scholar
  545. 534.
    Sharp JG, Thomas DB, Briscoe CV (1973) Effects of mustine hydrochloride on mouse haematopoietic and lymphoid tissues. Chemotherapy 18:304–313PubMedGoogle Scholar
  546. 535.
    Sharp JG, Thomas DB, Briscoe CV, Littlewood V (1975) Prolonged effects of nitrogen mustard on mouse haemotopoietic and lymphoid tissues. Scand J Haematol 14:313–319PubMedGoogle Scholar
  547. 536.
    Shnider BI, Gold GL, Hall T, Dederick M, Nevinny HB, Potee KG, Lasagna L, Owens AH, Hreschyshyn M, Selawry O, Holland JF, Jones R, Colsky J, Franzino A, Zubrod GG, Frei E, Brindley C (1960) Preliminary studies with cyclophosphamide. Cancer Chemother Rep 8:102–111Google Scholar
  548. 537.
    Shopsin B, Friedmann R, Gershon S (1971) Lithium and leukocytosis. Clin Pharmacol Ther 12:923–928PubMedGoogle Scholar
  549. 538.
    Sieber SM, Adamson RH (1975) Toxicity of antineoplastic agents in man: Chromosomal aberrations, antifertility effects, congenital malformations, and carcinogenic potential. Adv Cancer Res 22:57–155PubMedGoogle Scholar
  550. 539.
    Silini G, Elli R, Siracusa G, Pozzi LV (1968) Repopulation of the bone-marrow stem-cell compartment after irradiation. Cell Tissue Kinet 1:111–122Google Scholar
  551. 540.
    Simpson HW, Stoney PJ (1977) A circadian variation of melphalan (L-phenylalanine nitrogen mustard) toxicity to murine bone marrow: Relevance to cancer treatment protocols. Br J Haematol 35:459–464PubMedGoogle Scholar
  552. 540a.
    Sinclair WK (1965) Hydroxyurea: Differential lethal effects on cultured mammalian cells during the cell cycle. Science 150:1729–1731PubMedGoogle Scholar
  553. 541.
    Sladek NE (1973) Bioassay and relative cytotoxic potency of cyclophosphamide metabolites generated in vitro and in vivo. Cancer Res 33:1150–1158PubMedGoogle Scholar
  554. 542.
    Smart CR, Townsend LB, Rusho WJ, Eyre HJ, Quagliana JM, Wilson ML, Edwards CB, Mannings SJ (1975) Phase I study of ftorafur, an analog of 5-fluorouracil. Cancer 36:103–106PubMedGoogle Scholar
  555. 543.
    Smith LH, Clayton ML (1970) Distribution of injected 59Fe in mice. Exp Hematol 20:82–86Google Scholar
  556. 544.
    Smith WW, Wilson SM (1967) Effects of vinblastine and vincristine on survival and hemopoiesis in irradiated mice. J Natl Cancer Inst 39:1055–1066PubMedGoogle Scholar
  557. 545.
    Smith WW, Wilson SM (1970) Persistence of radiation damage: Hemopoietic effects in irradiated mice treated with actinomycin D. In: Stohlman F Jr (ed) Hemopoietic cellular proliferation. Grune & Stratton, New York, p 49–55Google Scholar
  558. 546.
    Smith WW, Alderman IM, Cornfield J (1961) Granulocyte release by endotoxin in normal and irradiated mice. Am J Physiol 201:396–402Google Scholar
  559. 547.
    Smith WW, Brecher G, Fred S, Budd RA (1966) Effect of endotoxin on the kinetics of hemopoietic colony-forming cells in irradiated mice. Radiat Res 27:710–717PubMedGoogle Scholar
  560. 548.
    Smith WW, Wilson SM, Fred SS (1968) Kinetics of stem cell depletion and proliferation: Effects of vinblastine and vincristine in normal and irradiated mice. J Natl Cancer Inst 40:847–854PubMedGoogle Scholar
  561. 549.
    Smith JP, Rutledge FN, Delclos L (1975) Postoperative treatment of early cancer of the ovary: A random trial between postoperative irradiation and chemotherapy. Natl Cancer Inst Monogr 42:149–153PubMedGoogle Scholar
  562. 549a.
    Spiro TE, Mattelaer M-A, Efira A, Stryckmans P (1981) Sensitivity of myeloid progenitor cells in healthy subjects and patients with chronic myeloid leukemia to chemotherapeutic agents. J Natl Cancer Inst 66:1053–1059PubMedGoogle Scholar
  563. 550.
    Spitz S (1948) The histological changes of nitrogen mustards on human tumors and tissues. Cancer 1:383–398PubMedGoogle Scholar
  564. 551.
    Spitzer G, Verma DS, Barlogie B, Beran MA, Dicke KA (1979) Possible mechanisms of action of lithium on augmentation of in vitro spontaneous myeloid colony formation. Cancer Res 39:3215–3219PubMedGoogle Scholar
  565. 552.
    Spurr CL, Jacobson LO, Smith TR, Guzman Barron ES (1943) The clinical application of a nitrogen mustard compound methyl-bis-(β-chloroethyl)-amine to the treatment of neoplastic disorders of the hemopoietic system. Cancer Res 7:51–52Google Scholar
  566. 553.
    Squires DJP, Lamerton LF (1975) The effect of various cytotoxic agents on bone marrow progenitor cells as measured by diffusion chamber assays. Br J Haematol 29:31–42PubMedGoogle Scholar
  567. 554.
    Stalzer RC, Kiely JM, Pease GL, Brown AL Jr (1965) Effect of 5-fluorouraeil on human hematopoiesis. Cancer 18:1071–1078PubMedGoogle Scholar
  568. 555.
    Standen G, Philip MA, Fletcher J (1980) The proliferative state of granulocytic progenitor cells in human blood and marrow. Cell Tissue Kinet 13:105–113PubMedGoogle Scholar
  569. 556.
    Stein RS, Beaman C, AH MY, Hansen R, Jenkins DD, Jume’an HG (1977) Lithium carbonate attenuation of chemotherapy-induced neutropenia. N Engl J Med 297:430–431PubMedGoogle Scholar
  570. 557.
    Stein RS, Hanson G, Koethe S, Hansen R (1977) An in vivo evaluation of lithium-induced granulocytosis. Blood [Suppl 1] 50:161Google Scholar
  571. 558.
    Stein RS, Hanson G, Koethe S, Hansen R (1978) Lithium-induced granulocytosis. Ann Intern Med 88:809–810PubMedGoogle Scholar
  572. 559.
    Stein RS, Flexner JM, Graber SE (1979) Lithium and granulocytopenia during induction therapy of acute myelogenous leukemia. Blood 54:636–641PubMedGoogle Scholar
  573. 560.
    Steinbach KH, Schick P, Trepel F, Raffler H, Döhrmann J, Heilgeist G, Heltzel W, Li K, Past W, van der Woerd-de-Lange JA, Theml H, Fliedner TM, Begemann H (1979) Estimation of kinetic parameters of neutrophilic, eosinophilic, and basophilic granulocytes in human blood. Blut 39:27–38PubMedGoogle Scholar
  574. 560a.
    Steinbach KH, Raffler H, Pabst G, Fliedner TM (1980) A mathematical model of canine granulocytopoiesis. J Math Biol 10:1–12PubMedGoogle Scholar
  575. 561.
    Stevens EE, Dicke KA (1976) Bone marrow transfusion in mice treated with BCNU. Proc Am Assoc Cancer Res 17:57Google Scholar
  576. 562.
    Stohlman F Jr, Quesenberry P, Niskanen E, Morley A, Tyler W, Rickard K, Symann M, Monette F, Howard D (1973) Control of granulopoiesis. In: Haemopoietic stem cells (Ciba Foundation Symposium 13). Elsevier Excerpta Medica/North Holland, Amsterdam London New York, pp 205–219Google Scholar
  577. 563.
    Stohlman F Jr, Quesenberry PJ, Tyler WS (1973) The regulation of myelopoiesis as approached with in vivo and in vitro techniques. Prog Hematol 8:259–297PubMedGoogle Scholar
  578. 564.
    Stolinsky DC, Pugh RP, Bateman JR (1975) 5-Fluorouracil therapy for pancreatic carcinoma: Comparison of oral and intravenous route. Cancer Chemother Rep 59:1031–1033PubMedGoogle Scholar
  579. 565.
    Stoller RG, Kenneth RH, Jacobs SA, Rosenberg SA, Chabner BA (1977) Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med 297:630–634PubMedGoogle Scholar
  580. 566.
    Stoller RG, Kaplan HG, Cummings FJ, Calabresi P (1979) A clinical and pharmacological study of high-dose methotrexate with minimal leucovorin rescue. Cancer Res 39:908–912PubMedGoogle Scholar
  581. 567.
    Storb R, Buckner CD, Dillingham LA, Thomas ED (1970) Cyclophosphamide regimens in rhesus monkeys with and without marrow infusion. Cancer Res 30:2195–2203PubMedGoogle Scholar
  582. 568.
    Straw JA, Talbot DC, Tailor GA, Harrap KR (1977) Some observations on the reversibility of methotrexate toxicity in normal proliferative tissue. J Natl Cancer Inst 58:91–97PubMedGoogle Scholar
  583. 569.
    Suit HD (1957) A technique for estimating the bone marrow cellularity in vivo using 59Fe. J Clin Pathol 10:267–269PubMedGoogle Scholar
  584. 570.
    Svoboda V (1974) Distribution of colony-forming cells in mouse bone marrow. Acta Haematol 51:113–120PubMedGoogle Scholar
  585. 571.
    Symoens J (1977) Levamisole, an antianergic chemotherapeutic agent: An overview. In: Chirigos M (ed) Control of neoplasia by modulation of the immune system. Raven, New YorkGoogle Scholar
  586. 572.
    Symoens J, Veys E, Mielants M, Pinals R (1978) Adverse reactions to levamisole. Cancer Treat Rep 62:1721–1730PubMedGoogle Scholar
  587. 573.
    Szmigielski S, Jeljaszewicz J (1976) Inhibition of normal granulopoiesis by cytostatic agents. Folia Haematol (Leipz) 103:678–685Google Scholar
  588. 574.
    Taketa ST, Carsten AL, Cohn SH, Atkins HL, Bond VP (1970) Active bone marrow distribution in the monkey. Life Sci 9:169–174PubMedGoogle Scholar
  589. 575.
    Talbot TR, Elson LA (1958) Protection of august rats against lethal doses of a dimethyl homologue of myleran by isologous bone marrow. Nature 181:684–686PubMedGoogle Scholar
  590. 576.
    Talley RW, Vaitkevicius VK (1963) Megaloblastosis produced by a cytosine antagonist, 1-β-D-arabinofuranosylcytosine. Blood 21: 352–362PubMedGoogle Scholar
  591. 577.
    Talley RW, O’Bryan RM, Tucker WG, Loo RV (1967) Clinical pharmacology and human antitumor activity of cytosine arabinoside. Cancer 20:809–816PubMedGoogle Scholar
  592. 578.
    Talley RW, O’Bryan RM, Gutterman JU, Brownlee RW, McCredie KB (1973) Clinical evaluation of cis-diamminedichloroplatinum (NSC-119875): Phase I clinical study. Cancer Chemother Rep 57:465–471PubMedGoogle Scholar
  593. 579.
    Tanaka T, Craig AW, Lajtha LG (1970) A kinetic study on murine myeloid leukaemia. Br J Cancer 24:138–148PubMedGoogle Scholar
  594. 580.
    Terasima T, Takabe Y, Katsumata T, Watanabe M, Umezawa H (1972) Effect of bleomycin on mammalian cell survival. J Natl Cancer Inst 49:1093–1100PubMedGoogle Scholar
  595. 581.
    Terry WD (1978) Concluding remarks. In: Terry WD, Windhorst D (eds) Immunotherapy of cancer: Present states of trials in man. Raven, New York, pp 669–671Google Scholar
  596. 582.
    Thiersch JB (1949) Bone marrow changes in man after treatment with aminopterin, amethopterin, and aminoanfol. Cancer 2:877–883PubMedGoogle Scholar
  597. 583.
    Thomas DB, Briscoe CV (1973) The effects of intravenous injections of endotoxin on the distribution of cells between murine blood and bone marrow. J Anat 114:407–419PubMedGoogle Scholar
  598. 584.
    Thomas ED, Fliedner TM, Thomas D, Cronkite EP (1965) The problem of the stem cell: Observations in dogs following nitrogen mustard. J Lab Clin Med 65:794–803PubMedGoogle Scholar
  599. 585.
    Thompson HS, Gale GR (1971) cis-Dichlordiammineplatinum (II): Hematopoietic effects in rats. Toxicol Appl Pharmacol 19:602–609PubMedGoogle Scholar
  600. 586.
    Till JE (1976) Regulation of hemopoietic stem cells. In: Cairnie AB, Lala PK, Osmond DG (eds) Stem cells of renewing cell populations. Academic Press, New York, pp 143–155Google Scholar
  601. 587.
    Till JE, McCulloch EA (1961) A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res 14:213–222PubMedGoogle Scholar
  602. 588.
    Tisman G, Herbert V, Rosenblatt S (1973) Evidence that lithium induces human granulocyte proliferation: Elevated serum vitamin B12 binding capacity in vivo and granulocyte colony proliferation in vitro. Br J Haematol 24:767–771PubMedGoogle Scholar
  603. 589.
    Torelli U (1977) An overlooked aspect of the mechanism of action of most antineoplastic drugs: The inhibition of macromolecular RNA metabolism. Eur J Cancer 13:1363–1368PubMedGoogle Scholar
  604. 590.
    Trainor KJ, Morley AA (1976) Screening of cytotoxic drugs for residual bone marrow damage. J Natl Cancer Inst 57:1237–1239PubMedGoogle Scholar
  605. 591.
    Trainor KJ, Seshadri RS, Morley AA (1979) Residual marrow injury following cytotoxic drugs. Leuk Res 3:205–210PubMedGoogle Scholar
  606. 592.
    Trainor KJ, Morley AA, Seshardi RS (1980) A proliferative defect of marrow cells in experimental chronic hypoplastic marrow failure (aplastic anaemia). Exp Hematol 8:674–682PubMedGoogle Scholar
  607. 593.
    Trouet A, Deperez-De Champeneere D, de Duve C (1972) Chemotherapy through lysosomes with a DNA-daunomycin complex. Nature (New Biol) 239:110–112Google Scholar
  608. 594.
    Trouet A, Deperez-De Champeneere D, de Smedt-Malengreaux M, Atassi G (1974) Experimental leukemia chemotherapy with a “lysosomotropic” adriamycin-DNA complex. Eur J Cancer 10:405–411PubMedGoogle Scholar
  609. 595.
    Twentyman PR (1972) Leucocyte response to bacterial endotoxin in mice pre-treated with cytotoxic agents. Br J Haematol 23:69–78PubMedGoogle Scholar
  610. 596.
    Twentyman PR, Bleehen NM (1973) The sensitivity to bleomycin of spleen colony-forming units in the mouse. Br J Cancer 28: 66–70PubMedGoogle Scholar
  611. 597.
    Udupa KB, Reissmann KR (1974) Acceleration of granulopoietic recovery by androgenic steroids in mice made neutropenic by cytotoxic drugs. Cancer Res 34:2517–2520PubMedGoogle Scholar
  612. 598.
    Udupa KB, Reissmann KR (1979) In vivo erythropoietin requirements of regenerating erythroid progenitors (BFU-e, CFU-e) in bone marrow of mice. Blood 53:1164–1171PubMedGoogle Scholar
  613. 599.
    Udupa KB, Okamura H, Reissmann KR (1972) Granulopoiesis during myleran-induced suppression of transplantable hematopoietic stem cells. Blood 39:317–325PubMedGoogle Scholar
  614. 600.
    Ujj G, Kovács P, Hernádi F (1979) In vitro estimation of the proliferative state of murine bone marrow colony forming units in culture (CFU-C) with hydroxyurea (HU). Biomedicine 31:61–62PubMedGoogle Scholar
  615. 601.
    Urabe A, Asano S, Sato N, Chiba S, Kosaka K, Chiyoda S, Mizoguchi H, Miura Y, Takaku F (1976) Recovery of bone marrow precursor cells after administration of cytosine arabinoside in mice. 16th Congr Int Soc Hematol, Kyoto 1976 (Abstr 0–14)Google Scholar
  616. 602.
    Uyeki EM, Pazdernik TL, El Askar A (1976) Toxicity of antitumor agents on hemopoietic colony-forming cells. J Pharmacol Exp Ther 198:246–253PubMedGoogle Scholar
  617. 603.
    Vaitkevicius VK, Talley RW, Tucker JL, Brennan MJ (1962) Cytological and clinical observations during Vincaleukoblastine therapy of disseminated cancer. Cancer 15:294–306Google Scholar
  618. 604.
    Valdivieso M, Bodey GP, Gottlieb JA, Freireich EJ (1976) Clinical evaluation of ftorafur (pyrirnidine-deoxyribose-N1–2-furanidyl-5-fluorouracil). Cancer Res 36:1821–1824PubMedGoogle Scholar
  619. 605.
    Valeriote FA, Bruce WR (1967) Comparison of the sensitivity of hematopoietic colony-forming cells in different proliferative states to vinblastine. J Natl Cancer Inst 38:393–399PubMedGoogle Scholar
  620. 606.
    Valeriote FA, Tolen SJ (1972) Survival of hematopoietic and lymphoma colony-forming cells in vivo following the administration of a variety of alkylating agents. Cancer Res 32:470–476PubMedGoogle Scholar
  621. 607.
    Valeriote FA, Van Putten L (1975) Proliferation-dependent cytotoxicity of anticancer agents: A review. Cancer Res 35:2619–2630PubMedGoogle Scholar
  622. 608.
    Valeriote FA, Bruce WR, Meeker BE (1966) Comparison of the sensitivity of normal hematopoietic and transplanted lymphoma colony-forming cells of mice to vinblastine administered in vivo. J Natl Cancer Inst 36:21–27PubMedGoogle Scholar
  623. 609.
    Valeriote FA, Collins DC, Bruce WR (1968) Hematological recovery in the mouse following single doses of gamma-radiation and cyclophosphamide. Radiat Res 33:501–511PubMedGoogle Scholar
  624. 610.
    Valeriote F, Vietti T, Tolen S (1973) Kinetics of the lethal effect of actinomycin D on normal and leukemic cells. Cancer Res 33:2658–2661PubMedGoogle Scholar
  625. 611.
    Valeriote F, Vietti T, Edelstein M (1976) Combined effect of cytosine arabinoside and thiopurines. Cancer Treat Rep 60:1925–1934PubMedGoogle Scholar
  626. 612.
    Valeriote FA, Vietti T, Coulter D (1980), Cytotoxicity of adriamycin combined with methotrexate against L1210 leukemia in mice. J Natl Cancer Inst 64:801–805PubMedGoogle Scholar
  627. 613.
    Van Putten LM (1974) Are cell kinetic data relevant for the design of tumor chemotherapy schedules? Cell Tissue Kinet 7:493–504PubMedGoogle Scholar
  628. 614.
    Van Putten LM, Lelieveld P (1970) Factors determining cell killing by chemotherapeutic agents in vivo. I. Cyclophosphamide. Eur J Cancer 6:313–321PubMedGoogle Scholar
  629. 615.
    Van Putten LM, Lelieveld P (1971) Factors determining cell killing by chemotherapeutic agents in vivo. II. Melphalan, chlorambucil and nitrogen mustard. Eur J Cancer 7:11–16PubMedGoogle Scholar
  630. 616.
    Van Putten LM, Lelieveld P, Kram-Idsenga LKJ (1972) Cell-cycle specificity and therapeutic effectiveness of cytostatic agents. Cancer Chemother Rep, Part 1 56:691–700PubMedGoogle Scholar
  631. 617.
    Van Putten LM, Lelieveld P, Kram-Idsenga LKJ (1973) Abhängigkeit der Wirksamkeit phasenspezifischer Zytostatika vom Zellzyklus: Interpretation von Dosis-Wirkungskurven. In: Wüst G (ed) Aktuelle Probleme der Therapie maligner Tumoren. Thieme, Stuttgart, pp 197–208Google Scholar
  632. 618.
    Van Putten LM, Kram-Idsenga LKJ, Pijpers-de-Bruin M (1974) A comparison of the cell killing in the mouse after exposure to ftorafur and to 5-fluorouracil. Br J Cancer 30:179–180PubMedGoogle Scholar
  633. 619.
    Vassort F, Frindel E, Tubiana M (1971) Effects of hydroxyurea on the kinetics of colony-forming units of bone marrow in the mouse. Cell Tissue Kinet 4:423–431PubMedGoogle Scholar
  634. 620.
    Vassort F, Winterholer M, Frindel E, Tubiana M (1973) Kinetic parameters of bone marrow stem cells using in vivo suicide by tritiated thymidine or by hydroxyurea. Blood 41:789–796PubMedGoogle Scholar
  635. 621.
    Vecchi A, Fioretti M, Mantovani A, Barzi A, Spreafico F (1976) The immunosuppressive and hematotoxic activity of imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazeno) in mice. Transplantation 22:619–624PubMedGoogle Scholar
  636. 622.
    Vodopick H, Hamilton HE, Jackson HL, Peng CT, Sheets RF (1969) Metabolic fate of tritiated busulfan in man. J Lab Clin Med 73:266–276PubMedGoogle Scholar
  637. 623.
    Vogel CL, Lipscomb DL, Silverman DA, Kerns AL, Mansell PW, Sugarbaker EU (1976) Levamisole granulocytopenia in patients receiving an adjuvant chemoimmunotherapy program after surgery for breast carcinoma with axillary lymph node involvement. Cancer Treat Rep 62:1587–1589Google Scholar
  638. 624.
    Vogel JM, Kimball HR, Wolff SM, Perry S (1967) Etiocholanolone in the evaluation of marrow reserves in patients receiving cytotoxic agents. Ann Intern Med 67:1226–1238PubMedGoogle Scholar
  639. 625.
    Vogel SJ, Presant CA, Ratkin GA, Klahr C (1979) Phase I study of thymidine plus 5-fluorouracil infusions in advanced colorectal carcinoma. Cancer Treat Rep 63:1–5PubMedGoogle Scholar
  640. 626.
    Vogler WR, Mingioli ES, Garwood FA (1973) The effect of methotrexate on granulocytic stem cells and granulopoiesis. Cancer Res 33:1628–1633PubMedGoogle Scholar
  641. 627.
    Vogler WR, Mingioli ES, Garwood FA (1972) Granulopoietic stem cell regulators in murine urine: Alterations in activity after methotrexate. J Lab Clin Med 79:379–387PubMedGoogle Scholar
  642. 628.
    Vos O (1972) Multiplication of haemopoietic colony-forming units (CFU) in mice after X-irradiation and bone marrow transplantation. Cell Tissue Kinet 5:341–350PubMedGoogle Scholar
  643. 629.
    Vos O, Buurman WA, Ploemacher RE (1972) Mobilization of haemopoietic stem cells (CFU) into the peripheral blood of the mouse: Effects of endotoxin and other compounds. Cell Tissue Kinet 5:467–479PubMedGoogle Scholar
  644. 629a.
    Wagemaker G, Visser TP (1980) Erythropoietin-independent regeneration of erythroid progenitor cells following multiple injections of hydroxyurea. Cell Tissue Kinet 13:505–517PubMedGoogle Scholar
  645. 629b.
    Wagemaker G, Peters MF, Bol SJL (1979) Induction of erythropoietin responsiveness in vitro by a distinct population of bone marrow cells. Cell Tissue Kinet 12:521–537PubMedGoogle Scholar
  646. 630.
    Wagner DE, Ramirez G, Weiss AJ, Hill G Jr (1971) Combination phase I-II study of imidazole carboxamide (NCS 45388). Oncology 26:310–316Google Scholar
  647. 631.
    Walker RI, Herion JC, Palmer JG (1962) Leukocyte kinetics studied by nitrogen mustard-induced alterations in DNA phosphorus labeling. Blood 20:72–76PubMedGoogle Scholar
  648. 632.
    Wallace HJ Jr, Higby DJ (1974) Phase I evaluation of cis-platinum(II)diamminedichloride (PDD) and a combination of PDD plus adriamycin. In: Connors TA, Roberts JJ (eds) Platinum coordination complexes in cancer chemotherapy. Springer, Berlin Heidelberg New York. Recent Results in Cancer Research, vol 48, pp 167–177Google Scholar
  649. 633.
    Ward HWC (1978) Central nervous system tumors of childhood treated with CCNU, vincristine, and radiation. Med Pediatr Oncol 4:315–320PubMedGoogle Scholar
  650. 634.
    Weiner RS, Richman CM, Yankee RA, Parker L (1979) Clinical results of autotransplantation after nitrosourea therapy. Exp Hematol [Suppl 5] 7:384–388PubMedGoogle Scholar
  651. 635.
    Wendling F, Tambourin P, Moreau-Gachelin F (1978) Incapacity of hematopoietic stem cell-deprived mice to produce tumor colonies induced by Friend virus-infected cells. Exp Hematol 6:777–784PubMedGoogle Scholar
  652. 636.
    Werner W, Haller M, Höpfner V, Küchler J, Ziervogel J (1971) Verlauf der hämatotoxischen Cyclophosphamidwirkung bei der Ratte. Exp Pathol (Jena) 5:123–127Google Scholar
  653. 637.
    Wheeler AG, Dansby D, Hawkins HC, Payne HG, Weikel JH (1962) A toxicologic and hematologic evaluation of cyclophosphamide (cytoxan) in experimental animals. Toxicol Appl Pharmacol 4:324–343PubMedGoogle Scholar
  654. 638.
    White FR (1959) New agent data summaries: Cytoxan. Cancer Chemother Rep 2:21–25Google Scholar
  655. 639.
    Wodinsky I, Swiniarski J, Kensler CJ (1967) Spleen colony studies of leukemia L1210. II. Differential sensitivities of normal and leukemic bone marrow colony-forming cells to single- and divided-dose therapy with cytosine arabinoside (NSC-63878). Cancer Chemother Rep 51:423–429Google Scholar
  656. 640.
    Wolmark N, Fisher B (1974) The effect of a single and repeated administration of Corynebacterium parvum on bone marrow macrophage colony production in syngeneic tumor-bearing mice. Cancer Res 34:2869–2872PubMedGoogle Scholar
  657. 641.
    Worton RG, McCulloch EA, Till JE (1969) Physical separation of hemopoietic stem cells from cells forming colonies in culture. J Cell Physiol 74:171–182PubMedGoogle Scholar
  658. 642.
    Wu C-T, Lajtha LG (1975) Hemopoietic stem cell kinetics during continuous radiation. Int J Radiat Biol 27:41–50Google Scholar
  659. 643.
    Yagoda A, Watson RC, Gonzalez-Vitale JC, Grabstald H, Whitmore WF (1976) cis-Dichlordiammineplatinum (II) in advanced bladder cancer. Cancer Treat Rep 60:917–923PubMedGoogle Scholar
  660. 644.
    Yoffey JM (1973) Stem cell role of the lymphocyte-transitional cell (LT) compartment. In: Haemopoietic stem cells. Elsevier/Excerpta Medica/North Holland, Amsterdam London New York (CIBA Foundation Symposium 13, pp 5–39)Google Scholar
  661. 645.
    Young RC, deVita VT (1970) The effect of chemotherapy on the growth characteristics and cellular kinetics of leukemia L1210. Cancer Res 30:1789–1794PubMedGoogle Scholar
  662. 646.
    Young RG, Walker MD, Canellos GP, Schein PS, Chabner BA, deVita VT (1973) Initial clinical trials with methyl-CCNU, 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-l-nitrosourea (MeCCNU). Cancer 31:1164–1169PubMedGoogle Scholar
  663. 647.
    Zuckerman KS, Sullivan R, Quesenberry PJ (1978) Effects of actinomycin D in vivo on murine erythroid stem cells. Blood 51:957–969PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1982

Authors and Affiliations

  • Hans-Peter Lohrmann
    • 1
  • Wolfgang Schreml
    • 1
  1. 1.Zentrum für Innere Medizin Abteilung Innere Medizin III (Hämatologie/Onkologie)Universität UlmUlmGermany

Personalised recommendations